Silikonielastomeerin koostumuksen optimointi kahdessa kontrolloidun lääkeannostelun sovelluksessa by Känkänen, Voitto
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VOITTO KÄNKÄNEN 
OPTIMIZATION OF SILICONE ELASTOMER FORMULATIONS 
FOR TWO CONTROLLED RELEASE DRUG DELIVERY  
PRODUCTS 
Master of Science Thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examiner: Professor Jyrki Vuorinen 
 
Examiner and topic approved in the 
Technical Sciences Faculty Council 
meeting on June 3, 2015 
ii 
 
ABSTRACT 
 
TAMPERE UNIVERSITY OF TECHNOLOGY 
Master’s Degree Programme in Materials Science 
KÄNKÄNEN, VOITTO: Optimization of Silicone Elastomer Formulations for 
Two Controlled Release Drug Delivery Products   
Master of Science Thesis, 92 pages, 8 appendix pages 
August 2015 
Major: Technical Polymer Materials 
Examiner: Professor Jyrki Vuorinen 
Keywords: Silicone, Silica, Diffusion, Controlled Release Drug Delivery 
 
The goal of controlled release (CR) is to improve the spatial and temporal presentation 
of an active pharmaceutical ingredient (API) in the body. It can, for example, reduce the 
systemic side effects of a drug, facilitate its absorption to the body and improve patient 
compliance and convenience.  
 
Polymers play an essential role in CR technology. Silicone polymers have been used as 
biomaterials for decades thanks to their biocompatibility and biostability and they have 
also found their place in controlled release applications.  Elastomer materials are usually 
compounded with large amounts of fillers to improve their properties. The most com-
mon filler for silicone elastomers is amorphous silica (silicon dioxide), which is mainly 
used to improve the mechanical properties of the material.  
 
In this work, the effect of silica concentration of a silicone elastomer on the drug release 
rate from two diffusion-controlled drug delivery devices is studied. The elastomer mate-
rial acts as a diffusion-controlling membrane in these two products. The goals of this 
thesis work were, firstly, to find a material composition that could be used for the two 
products and, secondly, to create a simple empirical model that could be used to predict 
drug release rates from the products. The performance of this material was also com-
pared with materials that were currently in use.   
 
The specimen manufacturing process consisted of typical elastomer processing, such as 
mixing, extrusion and heat vulcanization as well as product-specific assembly methods. 
Through material and specimen characterization and in vitro release rate analysis, suita-
ble material compositions were found and successful statistical models created, explain-
ing up to 97% of variance in drug release rate, depending on the studied time point and 
API. For one of the two active ingredients studied, it was found that the storage time 
between manufacturing and use must be controlled due to different diffusional proper-
ties of the API. This thesis acted as a step towards the introduction of these materials 
into product manufacturing.  
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Kontrolloidulla lääkeannostelulla (Controlled Release Drug Delivery) pyritään lääkeai-
neen annostelupaikan, -ajan ja -nopeuden optimointiin. Sen avulla voidaan muun muas-
sa vähentää lääkkeen systeemisiä sivuvaikutuksia, parantaa lääkkeen imeytymistä eli-
mistöön ja edistää potilaiden hoitomyöntyvyyttä.  
 
Polymeerit ovat hyvin keskeisessä osassa kontrolloidun lääkeannostelun tekniikassa. 
Silikonipolymeerejä on käytetty laajalti biomateriaaleina jo kymmeniä vuosia niiden 
biokompatibiliteetin ja biostabiilisuuden ansiosta ja niitä on hyödynnetty myös kontrol-
loidun lääkeannostelun sovelluksissa. Kuten elastomeerimateriaaleihin yleisesti, myös 
silikonielastomeereihin sekoitetaan merkittäviä määriä täyteaineita materiaalin ominai-
suuksien parantamiseksi. Silikonielastomeereilla yleisin käytetty täyteaine on amorfinen 
silika (piidioksidi), jota käytetään pääasiassa materiaalin mekaanisten ominaisuuksien 
parantamiseksi.  
 
Tässä työssä tutkittiin silikonielastomeerin silikapitoisuuden vaikutusta lääkeaineen 
vapautumisnopeuteen kahdesta eri tuotteesta, joissa materiaali toimii diffuusiota kont-
rolloivana membraanina. Lisäksi materiaalia verrattiin jo käytössä oleviin silikonielas-
tomeereihin. Työn tavoitteena oli yhtäältä löytää materiaalikoostumus, joka mahdollis-
taisi materiaalin käyttämisen molemmissa valmisteissa ja toisaalta luoda yksinkertainen 
empiirinen malli, joka kuvaisi materiaalin täyteainepitoisuuden vaikutusta tuotespesifi-
seen lääkeaineen vapautumisnopeuteen.  
 
Näytteenvalmistuksessa käytettiin tyypillisiä elastomeerien prosessointimenetelmiä, 
kuten sekoitusta, ekstruusiota ja lämpövulkanointia sekä tuotteille ominaisia kokoon-
panomenetelmiä. Materiaalien karakterisoinnin ja tuotenäytteiden in vitro vapautumis-
nopeusanalyysien avulla löydettiin käyttökelpoinen materiaalikoostumus molemmille 
tuotteille. Lisäksi toisella tuotteista havaittiin, että tuotteiden varastointiaikaa ennen 
käyttöä on kontrolloitava kyseisen lääkeaineen diffuusio-ominaisuuksien vuoksi. Va-
pautumisnopeutta mallinnettiin onnistuneesti lineaarisella regressiolla täyteainepitoi-
suuden sekä tuotteen dimensioita kuvaavan tekijän funktiona. Mallit pystyivät käytetys-
tä lääkeaineesta ja aikapisteestä riippuen selittämään jopa 97 % vapautumisnopeuden 
varianssista. Työ toimi askeleena kohti materiaalien käyttöönottoa.   
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MATHEMATICAL SYMBOLS 
 
𝑎 inner radius of a cylinder 
𝑏 outer radius of a cylinder 
𝑐  concentration 
𝑐1 concentration, when 𝑟 = 𝑎 
𝑐2 concentration, when 𝑟 = 𝑏 
𝑐𝑠 saturation concentration, solubility 
𝐷  diffusion coefficient, diffusivity 
𝐷𝐹 dimension factor 
𝑓  number of factors in an experiment 
𝐻  height of a cylinder 
𝐽  diffusional flux 
𝐽𝑥, 𝐽𝑦, 𝐽𝑧 diffusional fluxes in x, y and z-directions 
𝑘𝑎 constant in rate-law 
𝐾  partition coefficient 
𝑀𝑡 cumulative amount of drug released at time 𝑡  
𝑀∞  cumulative amount of drug released at infinite time 
𝑀𝑆𝐸 mean square error 
𝑀𝑆𝑇 mean square total variance 
𝑀𝑇𝑚𝑖𝑛 smallest membrane thickness in a cross-section 
𝑀𝑇𝑚𝑎𝑥 largest membrane thickness in a cross-section 
𝑛  sample size (except in Section 2.1) 
𝑛 exponent in reaction rate-law (only in Section 2.1) 
𝑝 statistical p-value 
𝑄𝑥, 𝑄𝑦, 𝑄𝑧 amount of substance diffusing into a volume element in unit 
time in x, y and z-directions  
𝑄𝑡  amount of substance diffusing out of a cylinder of unit 
length in time 𝑡 
𝑟  radius, radial distance from the center of a cylinder 
𝑅  correlation coefficient 
𝑅𝑅 release rate 
𝑅2  coefficient of determination 
𝑅𝑎𝑑𝑗
2   adjusted coefficient of determination 
𝑆𝑆𝐸 error sum of squares 
𝑆𝑆𝑇 total sum of squares 
𝑆 standard distance of data points from a regression line 
𝑆′ storage modulus 
𝑇𝐺𝐴 thermogravimetric residue (in weight-%) 
𝑥 position in x-direction or x-coordinate (only in Section 2.1)  
𝑥  predictor variable (except in section 2.1) 
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𝑥1, 𝑥2, 𝑥3, 𝑥4, 𝑥𝑖  predictor variables, i:th predictor variable, i:th value of the 
predictor variable 𝑥 
𝑋𝑖 i:th value of variable 𝑋 
?̅?  mean value of variable 𝑋 
𝑌𝑖  i:th value of variable 𝑌 
?̅?   mean value of variable 𝑌 
𝑦  position in y-direction or y-coordinate (only in Section 2.1)  
𝑦 response variable (except in section 2.1) 
𝑦𝑖 i:th value of the response variable 𝑦 
 
𝛼  statistical significance level 
𝛽0, 𝛽1, 𝛽2, 𝛽3, 𝛽4, 𝛽𝑖 regression coefficients, i:th regression coefficient 
?̂?0, ?̂?1, ?̂?2  estimated regression coefficients 
 𝜖 random error term, residual error 
𝜂∗ complex viscosity 
𝜔 angular frequency 
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ABBREVIATIONS 
 
 
ANCOVA Analysis of Covariance 
ANOVA Analysis of Variance 
API Active Pharmaceutical Ingredient  
BME Biomedical Engineering 
CDD  Controlled Drug Delivery 
CR Controlled Release 
DDS Drug Delivery System 
DoE Design of Experiments 
HPLC High Pressure Liquid Chromatography 
ID Inner Diameter 
LADME Pharmacokinetic sequence (Liberation, Absorption, Distri-
bution, Metabolism and Elimination) 
MLR Multiple Linear Regression 
OD Outer Diameter 
PDDS Polymeric Drug Delivery System 
PLA Poly(lactic acid) 
PLGA Poly(lactic-co-glycolic acid) 
PDMS Polydimethylsiloxane 
RTV Room Temperature Vulcanizing 
RSM Response Surface Methodology 
SD Standard Deviation 
SiO2 Silica, silicon dioxide 
TGA Thermogravimetry 
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1 INTRODUCTION 
At the core of this thesis work are so-called polymeric drug delivery systems (PDDS). In 
a PDDS, a polymer material, in one way or another controls the release of an active 
pharmaceutical ingredient (API) into a specific site within the human body. This tech-
nology is central to the products of Bayer Oy and since the polymer materials are essen-
tial for product performance, a considerable amount of work has been done on polymer 
development within the company. The present work is intended to act as a step forward 
towards the deployment of new silicone elastomer materials.  
 
One motivational aspect behind this study is the advantage of having several possible 
material providers. Alternative material sources help to ensure process continuity. In 
addition, having increased control over the polymerization and compounding processes 
yields, besides certainty and knowledge, also more flexibility, especially when material 
batch sizes are small.  
 
This thesis work concentrates on the development of two polymeric drug delivery prod-
ucts and it has two main objectives regarding the new materials. Firstly, it seeks to de-
termine, whether it is possible to find a single polymer formulation that could be used 
for both products in question. This would result in cost savings in the future, e.g., 
through increases in material batch sizes. Secondly, this work seeks to find correlations 
between vital process parameters and product performance and to express them via a 
simple statistical model that could be expanded and refined in further studies.  
 
To achieve these objectives, carefully planned designed experiments are conducted. 
Important variables within the manufacturing process are chosen and the experimenta-
tion is performed by varying and controlling their levels. The product manufacturing 
process involves several steps: preparation and extrusion of a drug-elastomer mixture, 
extrusion coating, post-curing and product assembly. All stages are monitored with in-
process controls. The measured response variable that represents product performance 
in this work is the in vitro release rate of an API from the product.  
 
This work is divided into six chapters, including this introductory chapter. In the second 
chapter, basic concepts of polymeric drug delivery technology, silicone elastomers, 
elastomer processing, experimental design and statistical analysis methods are dis-
cussed. Both the author and the examiner of this thesis come from a materials science 
and engineering background and the theoretical part of this thesis is constructed accord-
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ingly: rather elementary aspects of biomedical engineering, biomaterials and pharma-
cology are discussed, whereas a more advanced approach is taken on subjects related to 
materials processing and polymers.  
 
Chapter 3, Materials and Methods, describes the developed products in question, the 
specimen preparation process as well as the materials and analysis methods used in this 
study. Chapter 4, Results and Discussion, contains the gathered data and results ob-
tained through statistical analysis. The last chapter is reserved for conclusions and sug-
gestions for the direction of future studies.  
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2 THEORETICAL BACKGROUND 
2.1 Polymeric Drug Delivery 
 
This work concentrates on two products that share a common goal – they are medicinal 
products designed to release active pharmaceutical ingredients (API) in a controlled, 
predetermined manner. The performance of such products is based on controlled drug 
delivery (CDD) or controlled release (CR) technology. This section seeks to explain the 
principles and peculiarities of this modern field of medicine and technology. It begins 
by giving a brief introduction to the field of biomaterials and explaining some of the 
related terminology.  
2.1.1 Biomaterials Science and Biomedical Engineering 
In this thesis, engineering tools and methods are used in the development of medicinal 
products, which makes this work an example of biomedical engineering. The discipline 
of biomedical engineering (BME) integrates the fields of medicine and engineering and 
provides tools and equipment for diagnostics, treatment and research [1, p. 2]. The 
modern health care system is characterized by an immense variety of machines, devices 
and instruments, many of which are products of BME. For the purpose of this thesis, the 
most interesting branch of BME is the field of biomaterials.  
 
As discussed above, biomaterials are a branch of biomedical engineering. Quite similar-
ly, the science of controlled drug delivery originates from biomaterials science. Briefly 
put, biomaterials science is a field of science that studies materials with a special em-
phasis on their interactions with biological environments [2, p. xxvi]. It is a multidisci-
plinary endeavor, requiring expertise in chemistry, physics and biology, as well as med-
icine and engineering [2, p. xxv].  
 
A commonly accepted definition for a biomaterial is “A nonviable material used in a 
medical device, intended to interact with biological systems” (Williams (1987), as cited 
by Ratner et al.) [2, p. xxvi]. This broad definition also includes materials used in medi-
cal devices that are not in direct contact with the body, such as cell growing platforms in 
tissue engineering (where the cells are being grown outside the body) or tubings used in 
hemodialysis devices (which only come in contact with blood).  
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Biomaterials can be either synthetic or natural by origin [2, p. xxv]. All main material 
classes (plastics and elastomers, metals, ceramics and composites) have their representa-
tives in the biomaterial family [2, p. xxvii]. Examples of common biomaterial applica-
tions include prostheses, artificial joints (most commonly hip, knee and shoulder joints), 
catheters, stents, contact lenses and intraocular lenses, bone fixation screws and plates, 
breast implants and contraceptive intrauterine devices. Table 1 presents some bio-
materials used in various large-scale applications.    
 
Table 1: Examples of large-scale applications of biomaterials (modified from [2, p. xxvii]). 
Application Biomaterials used 
Implants for joint replacement Stainless steel, titanium, polyethylene 
Plates and screws for bone fixation Metals, poly(lactic acid) 
Bone cement Poly(methyl methacrylate) 
Pacemaker Titanium, polyurethane 
Hemodialysis Polysulfone, silicone 
Stent Stainless steel, other metals, poly(lactic acid) 
Catheter Teflon, silicone, polyurethane 
Contact lenses Acrylate/methacrylate/silicone polymers 
Sutures Poly(lactic acid), polydioxanone, polypropylene, 
stainless steel 
Breast implants Silicone 
Intrauterine devices Silicone, copper 
 
The concept of biocompatibility is central to the use of biomaterials. A broadly endorsed 
definition for biocompatibility is “the ability of a material to perform with an appropri-
ate host response in a specific application” (Williams (1987), as cited by Ratner et al.) 
[2, p. xxvii]. For example, in the process of implantation, tissue injury unavoidably oc-
curs, which initiates defense systems in the body. These include inflammation, wound 
healing process and so-called foreign body responses. Assessing how severe and long-
lasting these symptoms are plays a major part of determining an implant’s biocompati-
bility [2, p. 503].  
 
A complex set of factors determine the biocompatibility of a material. In addition, med-
ical devices or implants are generally constructed from multiple materials, and the bio-
compatibility of such a device is not necessarily a sum of the individual material com-
patibilities. Instead, the biocompatibility of such a device must be studied as a whole [2, 
p. xxvi].  
 
Through the years, as new inventions and applications have appeared, the definition of 
biocompatibility has also evolved. It can be argued that since the first biomaterial prod-
ucts came to market 60–70  years ago, biomaterials have experienced three generations 
of development regarding the host response [2, p. xxviii]. The first approach was to 
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choose materials that were not necessarily designed for medical applications but pos-
sessed sufficiently similar (mechanical) properties as the tissue they were used to re-
place and to ensure that they did not elicit a deleterious response in the body. In other 
words, the goal was bioinertness, to have minimum interaction with the living tissue. 
 
Shortly after, the second generation of biomaterial development began. In contrast to the 
first generation materials, the goal of these materials was to have controlled interactions 
with the host tissues [2, p. xxviii].  Termed bioactive, these materials were specifically 
designed to be used in biomedical applications. Examples of bioactive materials include 
those used in controlled drug delivery applications as well as bioresorbable and biode-
gradable materials that experience controlled degradation within the body, resulting in a 
safe, non-surgical removal of the material if all the degradation products are non-toxic.  
 
The third generation of biomaterial development is directed towards tissue engineering 
and regenerative therapeutics. The goal of regenerative therapeutics is to generate func-
tional tissue from patient’s own cells to compensate for the loss of organs or tissue 
caused by disease or trauma [2, p. xxix]. This strategy removes two issues encountered 
with transplants using donated organs, namely the lack of donors and possible transplant 
rejection due to low biocompatibility [3, p. 589].  
 
Biomaterials play an important role in tissue engineering as they are used to manufac-
ture scaffolds onto which functional tissue is grown. These scaffolds can be made of 
synthetic or natural, typically porous, bioresorbable polymer materials [2, p. xxix]. Dif-
ferentiated or undifferentiated (stem) cells, depending on the application, are seeded on 
the scaffold, the tissue is matured in vitro and the resulting construct is implanted. Suc-
cessful tissue replacements achieved thus far using tissue engineering in humans include 
bladders, trachea, skin and epithelium, bone and cartilage [2, p. xxix] [3, p. 589] [4].  
 
This study focuses on two (non-degradable) products that are designed to have interac-
tions with the body, more precisely to release a drug substance in a controlled manner. 
This means that they are bioactive and thus represent the second generation of bio-
material evolution. The following subsections treat the subject of drug delivery in great-
er detail.  
2.1.2 Pharmacokinetics 
Pharmacokinetics is a branch of pharmacology that studies the fate of a drug after its 
administration, i.e. what are the effects of the body on the drug. Pharmacodynamics, in 
contrast, studies the effects of the drug on the body. Pharmacokinetics can be thought of 
as a special case of chemical kinetics with the human body as the (bio)chemical envi-
ronment.  
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There are several motivational aspects to the study of pharmacokinetics. For a drug to 
be effective, a sufficient amount of the active ingredient must reach the target site in the 
body. However, increasing dosages can prove dangerous, since excessive drug concen-
trations can cause undesirable systemic side effects. Furthermore, several medical con-
ditions require uninterrupted medication for prolonged periods of time. This is why it is 
important to understand how the drug concentrations evolve within the body after a 
drug formulation has been administered. The optimum plasma concentration region is 
called the therapeutic window and it is limited by a minimum effective level and a max-
imum desired level of a drug. [2, pp. 1024–1025] [5, p. 16]. The ratio of the two levels is 
called the therapeutic index. The lower the therapeutic index of a drug, the more accu-
rate dosage is required for safe and effective treatment.  
 
Clinical study of pharmacokinetics usually involves measurements of drug concentra-
tion in the blood or other bodily fluids as the drug is administered.  Concentration data 
can be used to determine safe and effective ranges for the drug dosage, even though the 
relationship between plasma concentration and a response can in fact be quite complex 
[6, p. 176].  
 
What happens to an API after a drug formulation has been administered can be de-
scribed by the LADME sequence: Liberation of the API from the carrier unit, absorption 
into the bloodstream, distribution within the body, metabolism by the body and excre-
tion (or elimination) from the body [2, p. 1024] [6, p. 176]. The sequence is described 
below in greater detail.  
 
With intravenous injections, practically the entire administered dose reaches the system-
ic circulation, whereas with oral formulations, a large part of the drug is lost due to in-
complete absorption in the gastrointestinal tract (i.e. poor bioavailability) and so-called 
first-pass metabolism in the liver and the gastrointestinal tract [6, p. 177]. The amount 
that reaches the systemic circulation is then distributed in the blood throughout the 
body, moving in and out of tissues. Some tissues absorb the active ingredient more rap-
idly and to a larger extent than others, depending on different binding effects, active 
transport mechanisms, the extent of blood perfusion and other factors [6, p. 177] [5, pp. 
8–10]. Once in the systemic circulation, a drug molecule is susceptible to metabolism 
(biochemical reactions that transform it into another molecule) and excretion (elimina-
tion of the substance from the plasma). Metabolism and excretion are, for the most part, 
accomplished by the liver and the kidneys, respectively [2, p. 1024] [6, p. 178].   
 
The rate of absorption, drug distribution in the system, and the rates of metabolism and 
excretion are largely defined by the biochemical properties of an API. Liberation, how-
ever, can be controlled by modifying the drug formulation, i.e., properties of the carrier 
and the excipients it consists of. This is precisely what controlled release technology is 
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for. Various approaches to controlled drug release and designs for the drug carriers are 
presented in the following two subsections. 
 
2.1.3 Controlled Release 
The goal of controlled release technology is to improve the spatial and temporal presen-
tation of a drug, i.e., to enable the introduction of an active ingredient to a desired loca-
tion within the body at a certain moment in time or during a certain period of time [5, p. 
19].  This can result in increased efficiency and decreased side effects as well as im-
proved patient compliance and safety. A true controlled release system has a predictable 
and reproducible drug release profile that is relatively independent of environmental 
conditions [7, p. 2].  
 
An obvious advantage of controlled release formulations is illustrated in Figures 1 and 
2, which show simple pharmacokinetic curves for two drug formulations. Figure 1 rep-
resents a conventional multiple dose (oral or intravenous) formulation and Figure 2 a 
single-dose near zero-order controlled release (CR) formulation. With the multiple dose 
formulation, the drug concentration fluctuates constantly between potentially harmful 
and ineffective levels, increasing after each dose, reaching a peak value and collapsing 
again. With the CR formulation, the concentration stays well within the therapeutic 
window for the majority of the time.  
 
 
Figure 1: A simple pharmacokinetic curve 
for a conventional multiple dose formulation 
(based on illustrations in [2]). 
 
One could argue that the variations in drug concentration could be smoothed out simply 
by shortening the dosage intervals to provide a more steady supply of drug. However, 
this is not feasible due to issues with patient compliance, especially for drugs with low 
therapeutic indices [8, pp. 1–2]. At present, the treatment of many of the globally most 
common medical conditions require regular intake of pharmaceuticals and the effective-
ness of the treatment depends heavily on patient compliance.  
 
With certain drug delivery systems (DDS), such as long acting implants, dosage inter-
vals can be extended to several years, reducing or removing problems with medical 
 
Figure 2: A simple pharmacokinetic curve 
for a single-dose near zero-order CR formu-
lation (based on illustrations in [2]). 
 8 
compliance, as patients no longer have to remember to take the medication and drug 
abuse and misuse become very difficult. As overall drug levels in the body are mini-
mized and a stable supply of active ingredient is achieved, controlled drug delivery can 
provide both safe and effective treatments that require little attention between doses.  
 
A variety of DDS for different administration routes and active ingredients have been 
developed over the years. Polymers play an important role as excipients in most of these 
systems. Some are designed to last for hours, others for several years. In their textbook, 
Ratner et al. have divided the contemporary DDS into five classes: injected nanocarri-
ers, injected depot DDS, implants and inserts, smart DDS, transdermal DDS and oral 
DDS [2, pp. 1024–1087].  
 
Intravenously injected nanocarriers include so-called PEGylated systems (bonded to 
poly(ethylene glycol)), polymeric micelles, liposomes, dendrimers, polymer-drug con-
jugates, polymer-drug polyelectrolyte complexes and drug nanoparticles [2, p. 1027]. 
Besides prolonging the liberation of an API using the methods above, it is also possible 
to influence another pharmacokinetic parameter, namely distribution.  This is achieved 
by attaching targeting ligands to drug nanoparticles to increase their affinities towards 
certain tissues [5, pp. 29, 41]. 
 
Injected depot DDS differ from injected nanocarriers by their size. The dimensions of 
injected depot carriers are usually in the order of micrometers. They are essentially bio-
degradable polymer microparticles or phase separating drug/polymer solutions. At pre-
sent, PLA and PLGA  (poly(lactic acid) and poly(lactic-co-glycolic acid)) copolymers 
are the most common materials for injected depot DDS, though various exotic material 
concepts have been introduced, including polymers and gels that exhibit in situ cross-
linking, precipitation or solidification [2, pp. 1055–1060].  
 
Non-degradable CDD implants and inserts are commonly made of silicone polymers, 
ethylene vinyl acetate copolymers, acrylate (co)polymers, vinylidene fluoride copoly-
mers or urethanes [2, p. 1063]. Degradable implants are usually made of various differ-
ent copolymers, featuring lactic acid and glycolic acid polymers, polyanhydrides, 
poly(ethylene glycols), poly(ortho esters) and poly(phosphoesters) [2, p. 1065]. The 
devices are, for the most part, of the monolithic type or of the reservoir type. The de-
signs are discussed in greater detail in subsection 2.1.4.  
 
While transdermal (through-the-skin) medication usually involves simple creams and 
ointments, several CDD systems have also been developed for this administration route. 
Typically in the form of a patch, these systems feature a rate-controlling membrane that 
dictates the maximum amount of drug that can enter the body through the skin, (provid-
ed that the skin has a higher permeability to the drug than the membrane does) [2, p. 
1075]. Controlled release technology can also tackle problems in oral formulations, 
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namely poor bioavailability, stability, solubility and absorption of drugs [2, p. 1083]. 
For example, an orally administered DDS can be designed to delay the drug release to 
protect the drug from the acidic environment of the stomach.  
 
Though constant (zero-order) release is often desirable, it is not always the optimum 
release profile [2, p. 1025]. Smart drug delivery devices react to changes in their envi-
ronment, and alter their drug release rates accordingly, in a controlled manner. Possible 
stimuli include, for instance, temperature, pH, enzymes, ultrasound and electromagnetic 
fields [2, pp.1071–1072] [9–11]. The release rate could follow biological rhythms such 
as menstrual or circadian rhythms or it could increase as blood glucose levels go up [12] 
[13].  
 
2.1.4 Temporal Control of Drug Release 
There are several ways to classify CDD devices and formulations, such as by size, bio-
degradability, administration route, time of use, etc. The present work focuses specifi-
cally on drug release rates, i.e., the temporal control of drug release. Thus, the classifi-
cation of devices is made according to the means by which drug release rate is con-
trolled and the processes that govern the release. Smart DDS, reacting to external (ex-
tracorporeal) stimuli or feedback from the body are not discussed here.  
 
The mechanisms that result in drug release from a carrier include drug dissolution, par-
titioning, diffusion, osmosis, material swelling and erosion [5, p. 30]. In addition, specif-
ic enzymatic or hydrolytic reactions can alter the release kinetics [7, p. 6]. Furthermore, 
distribution of drug nanoparticles within the body and thus the ultimate location of drug 
release can be influenced by targeting.  
 
It is worth noting, that often the drug is released by more than one mechanism and dif-
ferent mechanisms may be involved at different stages of the process [5, p. 19]. For ex-
ample, in a bioerodible system, material swelling, water penetration and drug diffusion 
in the swollen matrix may constitute a major part of the overall drug release, even if 
erosion would be the primary mechanism of release. The kinetics of each step must be 
evaluated and important, rate-determining steps identified if a thorough understanding 
of the release is to be achieved. The following subsections classify CDD systems ac-
cording to their dominant release mechanisms. Diffusion controlled systems are dis-
cussed in greatest detail, since the present study focuses on such devices.  
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2.1.4.1 Diffusion Controlled Systems 
Diffusion of active agents in a polymer matrix  
Diffusion occurs through random collisions of particles due to the kinetic energy they 
possess as heat and it causes concentration gradients to smooth out over time. Macro-
scopically, diffusion in an isotropic material can be analyzed using Fick’s first law  
 
𝐽 = −𝐷
𝜕𝑐
𝜕𝑥
  ,        (2.1) 
 
where 𝐽 is the diffusion flux (amount of substance passing through a unit of area in a unit 
of time) 𝐷 is the diffusivity or the diffusion coefficient, 𝑐 is the concentration of the dif-
fusing species and 𝑥 denotes the position [7, p. 11] [14, p. 505] [15, p. 2].  
 
Diffusivity is a proportionality constant that represents a species’ mobility in a diffusion 
medium and it may depend on concentration and various other variables [5, p. 31] [7, p. 
11]. Several factors can affect the diffusion of a drug in a polymer matrix. These include 
composition, molecular weight distribution and morphology of the polymer, as well as 
concentration of the diffusing species [7, p. 15]. The last one is known to have a very 
significant effect on molecular diffusivity in polymers [15, p. 2].  
 
Various different methods and theoretical models have been developed for determining 
and predicting diffusivities and solubilities of organic molecules in polymer materials 
[5, pp.143–150] [16–19]. Quantification of these two parameters is crucial if mechanis-
tic models are to be used to predict drug release.  If the diffusivity of a species in the 
system is known, Fick’s first law can be used to calculate the rate of diffusion in a sys-
tem irrespective of the actual mechanisms by which diffusion occurs [7, p. 11]. Fick’s 
first law assumes that the driving force of diffusion is the concentration gradient of a 
species. Even though this is a proper approximation in many cases, the driving force is 
more precisely the chemical potential gradient [7, pp. 11–12].  
 
Let us consider diffusion through a volume element that has edges of lengths 2𝑑𝑥, 2𝑑𝑦 
and 2𝑑𝑧 in a Cartesian coordinate system. At the center of this element, is point P. In 
point P, the diffusional flux in the x-direction is 𝐽𝑥. Through one of the two faces of the 
volume element perpendicular to the x-axis, the diffusional flux into the element is then 
(𝐽𝑥 −
𝜕𝐽𝑥
𝜕𝑥
)𝑑𝑥 and through the opposite face it is (𝐽𝑥 +
𝜕𝐽𝑥
𝜕𝑥
)𝑑𝑥. Thus, the quantity of ma-
terial accumulating into the element per time unit in the x-direction, 𝑄𝑥, is 
 
𝑄𝑥 = 𝑑𝑥2𝑑𝑦2𝑑𝑧 (𝐽𝑥 −
𝜕𝐽𝑥
𝑑𝑥
) + 𝑑𝑥2𝑑𝑦2𝑑𝑧 (𝐽𝑥 +
𝜕𝐽𝑥
𝜕𝑥
)  
      = −8𝑑𝑥𝑑𝑦𝑑𝑧 (
𝜕𝐽𝑥
𝜕𝑥
)        
 
Performing similar calculations for y- and z-directions yields  
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𝑄𝑦 = −8𝑑𝑥𝑑𝑦𝑑𝑧 (
𝜕𝐽𝑦
𝜕𝑦
)       
𝑄𝑧 = −8𝑑𝑥𝑑𝑦𝑑𝑧 (
𝜕𝐽𝑧
𝜕𝑧
)        
 
The total change in concentration in the element per time unit can be calculated by di-
viding the amounts of accumulated material per time unit with the total volume of the 
element, yielding 
 
𝜕𝑐
𝜕𝑡
=
𝑄𝑥+𝑄𝑦+𝑄𝑧
8𝑑𝑥𝑑𝑦𝑑𝑧
 ,  
 
𝜕𝑐
𝜕𝑡
= −
𝜕𝐽𝑥
𝜕𝑥
−
𝜕𝐽𝑦
𝜕𝑦
−
𝜕𝐽𝑧
𝜕𝑧
  ,      (2.2) 
 
and finally by differentiating the diffusion fluxes according to Equation (2.1), assuming 
that diffusivity is independent of position (x, y, z), we arrive at the three-dimensional 
presentation of Fick’s second law [15, pp. 3–4] [20, pp. 1–3]:  
 
𝜕𝑐
𝜕𝑡
= −𝐷 (
𝜕2𝑐
𝜕𝑥2
+
𝜕2𝑐
𝜕𝑦2
+
𝜕2𝑐
𝜕𝑧2
) .       (2.3) 
 
Several analytical solutions for Equation (2.3) can be found in the literature for rectan-
gular, cylindrical and spherical geometries [7] [15]. If the diffusion coefficient cannot 
be assumed independent of concentration, time and position, solving Fick’s second law 
analytically becomes difficult. However, numerical techniques with certain approxima-
tions can be used to model diffusion with non-constant diffusion coefficients.  
 
According to McGregor, as cited by Fan and Singh, depending on the porosity and pore 
size distribution of the polymer matrix, different models can be used to evaluate the 
diffusion behavior [7, p. 15]. If the pores are small with respect to the sizes of diffusing 
molecules, intimate molecular interactions between the polymer molecules and the dif-
fusing species should be included in the model. This is the case for macroscopically 
homogeneous polymers. In contrast, if the pores are significantly larger than the mean 
free paths of the diffusing species, the transport process mainly occurs in the fluid with-
in the pores and the polymer phase acts as little more than a container.  
 
The free volume theory proposes that the total volume a liquid occupies consists of the 
actual volume of molecules and the free volume between the molecules [7, p. 16]. The 
actual volume is independent of temperature, whereas free volume is proportional to 
temperature and has a zero value at the absolute zero. This theory has been further ap-
plied to several polymer-solvent systems and can be used to model diffusion in macro-
scopically homogeneous polymers.  
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The free volume theory of diffusion views the solute and polymer molecules as having 
impermeable cores surrounded by microscopic voids of free volume [5, p. 33]. As the 
system is constantly fluctuating due to thermal energy, these voids change in size and 
distribution so that occasionally a diffusing particle can pass through. Due to increasing 
molecular mobility, the probability of obtaining a large enough void increases with 
temperature. The proportionality constant between free volume and temperature chang-
es abruptly at the glass transition temperature (𝑇𝑔) of a polymer as do the mechanisms 
of diffusion [7, pp. 15–22] [21, p. 383] [14, p. 500].  
 
As mentioned before, changes in polymer composition through copolymerization or 
blending or simply by the addition of water, can cause the free volume of a polymer 
matrix to increase and augment the diffusivity as well [5, pp. 33–34]. Furthermore, crys-
tallinity of a matrix can reduce the diffusion rates significantly, as crystalline regions 
possess significantly less free volume than amorphous regions and are virtually impene-
trable to drug molecules [5, p. 34]. The effect of fillers on diffusion in silicone elasto-
mers is discussed in subsection 2.2.4.   
 
Diffusion controlled systems 
 
In a true diffusion controlled system, the drug release rate is determined solely by the 
rate of diffusion of an active agent through one or more components of the device [7, p. 
44]. Diffusion controlled drug delivery systems can be divided into two main catego-
ries: monolithic and reservoir systems. Monolithic systems consist of a homogeneous 
mixture of drug and polymer, whereas reservoir systems are characterized by a drug 
core surrounded by a rate-controlling membrane [7, p. 9] [5, p. 32]. Figure 3 shows a 
schematic illustration of drug release from the two types of diffusion controlled DDS. 
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Figure 3: A schematic illustration of the drug release process from monolithic and res-
ervoir-type controlled drug delivery devices. 
 
When introduced in vivo, monolithic devices show a strong initial burst of drug release 
as drug is dissolved rapidly from the surface. Simultaneously, new drug diffuses to the 
surface from inside the device and an evolving concentration gradient is formed. If the 
formulation is such, that the active ingredient is dissolved in the polymer matrix, the 
process of drug release from a monolithic device involves [7, p. 9] 
 
1) Diffusion to the device surface 
2) Partition between the matrix and the surrounding medium at the surface 
3) Transport from the device surface  
 
If, instead, the drug is dispersed as particles in the matrix, it first needs to dissolve into 
the polymer matrix before it can start to diffuse to the device surface [7, p. 9]. This is 
the case if the matrix is saturated with drug.  
 
As time progresses and drug concentration near the surface diminishes, the overall re-
lease rate decreases as the drug molecules have to diffuse a longer distance to reach the 
device surface, resulting in a non-zero-order release profile. This can be overcome with 
exotic geometries and coatings, but it is often unfeasible [5, p. 33]. Release from a 
monolithic system has been successfully described by the Higuchi model derived from 
Fick’s second law and other models based on Higuchi’s work [5, pp. 141–142] [22] 
[23]. Specific equations for monolithic devices are not discussed here.  
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If the matrix has a porous structure, the cavities may either obstruct the diffusion (if the 
pores are empty) or enhance the diffusion (if the pores contain the external dissolution 
medium), resulting in several steps of dissolution, partition and diffusion [7, pp. 9–10]. 
This phenomenon can also occur in the membranes of reservoir-type systems. In addi-
tion, too slow drug transport from the device surface results in non-zero API concentra-
tions at the surface, which can affect the total rate of diffusion from the device, as can 
be seen from Equation 2.1. This applies for both monolithic and reservoir type devices.   
 
Reservoir systems, in contrast to monolithic systems, can provide a zero-order release 
profile. These systems, also known as membrane-controlled systems, feature a reservoir 
of drug surrounded by a polymer membrane. A significant burst release can occur with 
these systems as well, since drug diffuses to the membrane from the reservoir during 
storage [7, p. 51]. After administration, the concentration gradient becomes more or less 
linear, as concentration near the surface approaches zero. If the reservoir core is loaded 
with drug in excess of its solubility, the device is said to have a constant activity source 
[5, p. 130]. As long as the core remains saturated with drug, the drug will diffuse 
through the membrane at a constant rate [14, p. 519] [7, p. 9].  
 
In reservoir systems, the release process follows the following sequence [7, p. 9]:  
 
1) Diffusion within the reservoir core  
2) Dissolution to membrane or partition between core and membrane matrices 
3) Diffusion through the membrane to the device surface  
4) Partition between membrane and surrounding medium 
5) Transport from the device surface 
 
It is essential that the membrane is and remains intact throughout the use of the device, 
especially if the drug in the reservoir is not bound to any solid carrier material, since 
even a small crevice or puncture in the membrane could cause the drug to leak out, ruin-
ing the designed release kinetics [5, p. 33]. The carrier material must have a low enough 
viscosity to enable a stable, thorough contact with the membrane, but it should not be 
able to diffuse through the membrane [7, pp. 39–40].  
 
Drug diffusion from a cylindrical reservoir-type device 
 
The devices studied in this work are mainly of the reservoir type. Assuming, that diffu-
sion through the membrane is the rate-limiting step, mathematical diffusion models can 
be used to predict drug release rate from such devices. Fick’s second law for a long, 
cylindrical reservoir device can be written as 
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𝜕𝑐
𝜕𝑡
=
1
𝑟
𝜕
𝜕𝑟
(𝑟𝐷
𝜕𝑐
𝜕𝑟
) ,       (2.5) 
 
where 𝑟 is the radius or the radial distance from the center of the cylinder [15, p. 69] 
[20, p. 3]. This equation assumes that the diffusion is completely radial, meaning that 
end effects are negligible.  
 
If the diffusion coefficient is assumed to be independent of position (and thus concen-
tration), a solution can be found for steady-state diffusion from a hollow cylinder. The 
steady-state condition can be expressed as 
 
𝑑
𝑑𝑟
(𝑟
𝑑𝑐
𝑑𝑟
) = 0,       𝑎 < 𝑟 < 𝑏       (2.6) 
 
where 𝑎 and 𝑏 are the inner and outer radii of the cylinder [15, p. 69]. A general solu-
tion for 𝑐 is given by  
 
𝑐 = 𝐴 + 𝐵 𝑙𝑛 𝑟 ,        (2.7) 
 
where A and B are constants that correspond to boundary conditions 𝑟 = 𝑎 and 𝑟 = 𝑏. 
If the concentrations at the surfaces are kept constant, 𝑐 can be expressed as  
 
𝑐 =
𝑐1 ln(𝑏/𝑟)+𝑐2 ln(𝑟/𝑎) 
ln(𝑏/𝑎)
 ,       (2.8) 
 
where 𝑐1 is the concentration at 𝑟 = 𝑎 and 𝑐2 is the concentration at 𝑟 = 𝑏 [15, p. 69]. 
The resulting concentration profile across the membrane in the case that 𝑐2 = 0 is plot-
ted in Figure 4 below.  
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Figure 4: A graph presenting the concentration profile across the membrane for three 
different 𝒃/𝒂 ratios for a cylindrical device. Zero concentration at the outer surface, 
constant diffusivity and steady-state diffusion are assumed. 𝒄 is the concentration at 
position 𝒓, 𝒂 is the inner and 𝒃 the outer radius of the membrane and 𝒄𝟏 is the reservoir 
drug concentration.   
Furthermore, 𝑄𝑡, the amount of substance diffusing in time t through unit length of the 
cylinder can be written as [15, p. 69] 
 
𝑄𝑡 =
2𝜋𝐷𝑡(𝑐2−𝑐1)
ln(𝑏/𝑎)
 .       (2.9) 
 
If diffusivity is assumed constant or if the concentration dependence of diffusivity is 
known for the polymer-API-combination, this mechanistic model could be used to pre-
dict the steady-state release rate of an active agent from a cylindrical reservoir device 
that fulfills the following requirements:  
 
1) The rate of diffusion through the ends of the device must be negligible. 
2) Surface concentrations must remain constant.  
3) The membrane material must be homogeneous.  
 
Equation (2.9) can also be presented in another form for devices with constant activity 
sources. As discussed earlier, if we assume that the reservoir is loaded with an excess of 
drug and drug transport from the device surface is rapid, a constant diffusional flux is 
achieved. In this case, the amount of drug released from a cylindrical device follows the 
equation 
 
𝑑𝑀𝑡
𝑑𝑡
=
2𝜋𝐻𝐷𝐾𝑐𝑠
ln(𝑏/𝑎 )
 ,       (2.10) 
 
where 𝑀𝑡 is the cumulative amount of drug released at time 𝑡, 𝐻 is the height of the 
cylinder, 𝐾 is the partition coefficient for the drug between the reservoir and the mem-
brane and 𝑐𝑠 is the saturation concentration of drug in the reservoir [5, p. 135] [24].  
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2.1.4.2 Swelling Controlled Systems 
A polymeric drug delivery system is usually classified as swelling controlled if swelling 
of the polymer network is a significant step in the overall drug release from the system. 
Overall, drug release from a swelling-controlled PDDS occurs by the following physical 
phenomena: water diffusion, polymer chain relaxation, polymer dissolution, drug disso-
lution and drug diffusion (followed by drug transport from the device surface) [5, p. 
153]. Depending on the rates of these successive steps, one or many of them may de-
termine the overall release rate from the device.  
 
As water penetrates a polymer network in high enough concentrations, it will induce a 
polymer chain relaxation process. The concentration of water needed to induce this pro-
cess depends on the physicochemical nature of the polymer. As the polymer chains “re-
lax”, their molecular mobility is increased significantly and the system increases in vol-
ume [5, pp. 153–154]. The kinetics of drug transport in these two states (non-swollen 
vs. swollen) are fundamentally different. In an ideal case, if polymer chain relaxation is 
the slowest step and if the surface area of the swelling front does not change with time, 
the overall release will follow zero-order kinetics [5, p. 158].  
 
Since hardly any swellable device exhibits purely swelling-controlled release and none 
of the aforementioned steps of the release process are instantaneous, moving fronts and 
boundaries (see Figure 5) will form within the system [5, pp. 158–160] [7, pp. 110–
113]. Let us consider a case where the system is loaded with an excess of drug, resulting 
in undissolved drug as particles in the matrix. At the center of the device, there will be a 
non-swollen, unaffected part of the system. As water penetrates the system, a moving 
swelling front is formed. The swelling front consists of incompletely swollen material 
containing dissolved drug molecules and, if drug dissolution is slow, also undissolved 
drug particles. Some undissolved drug may also be present in the swollen polymer net-
work, creating a diffusion front. The dissolved drug diffuses, down its concentration 
gradient, in the swollen polymer network, out of the device and into the surrounding 
fluid. At the outer edges of the device, there may even be an erosion front, if the swol-
len polymer is susceptible to erosion.  
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Figure 5: A schematic presentation of the drug release process from a swellable drug 
delivery device in one dimension. Diamonds represent undissolved drug particles and 
small circles represent dissolved drug molecules. 
Since the diffusional behavior of a drug is fundamentally different in different regions 
of the partly swollen system, modelling overall release rate for a swellable system is 
challenging. A simple, general equation for drug release from a swellable system can be 
written in the form 
 
𝑀𝑡
𝑀∞
= 𝑘𝑎𝑡
𝑛 ,         (2.11) 
 
where 𝑀𝑡 is the cumulative amount of drug released at time 𝑡, 𝑀∞ is the total amount of 
drug released at infinite time and 𝑘𝑎 and 𝑛 are constants dependent on the nature of in-
teractions between the matrix polymer, the penetrating solvent and the API [7, pp. 126–
127] [5, p. 158]. For example, if 𝑛 = 0.5, drug release rate is controlled by Fickian dif-
fusion, meaning that drug diffusion is the lowers step in the process. Additionally, if 
𝑛 = 1.0, drug release rate is controlled by the advancement of the swelling front. In this 
case, diffusivity of drug in the swollen region is much faster than in the non-swollen 
region. The rate of drug diffusion must also be much higher than the rate of solvent dif-
fusion.  
 
A large variety of models have been developed to study the penetration of a solvent into 
a polymer matrix with different sets of assumptions and varying success [7, pp. 120–
124]. Furthermore, the combined effects of the various phenomena on the overall re-
lease have been studied extensively and several rather complex sets of equations for 
predicting the drug release rate can be found in the literature, of which only some can be 
analytically solved [7, pp. 130–152].  
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2.1.4.3 Erosion Controlled Systems 
In erosion controlled systems, mass loss of the system controls, to a significant degree, 
the release of a drug. Thus, the polymer is an active participant in the drug release pro-
cess. In an ideal erosion controlled device, the drug molecules are physically or chemi-
cally immobilized in the polymer matrix and released only by its erosion [7, p. 89]. This 
implies that the total release rate is directly proportional to the erosion rate. In reality, 
however, the overall release rate is determined by the rates of various different process-
es.  
 
The term erosion refers to mass loss of the system, whereas degradation refers more 
specifically to polymer chain cleavage leading to small molecular weight degradation 
products that can be eliminated by the body [5, p. 172]. Degradation can be seen as one 
step of erosion. Erosion also includes water uptake, changes in the structural integrity of 
the material and physical removal of the material into its surroundings [5, p. 173].  
 
Erosion controlled devices are usually monolithic systems, though reservoir-type sys-
tems exist as well [7, p. 5]. In all erosion-controlled systems, water uptake is an essen-
tial part of the process.  Erosion of a polymeric device (through aqueous hydrolysis) has 
several steps [5, p. 180]:  
 
1) Wetting of the device surface 
2) Diffusion of water into the matrix 
3) Polymer degradation and, if possible 
4) Removal of degradation products through diffusion 
 
Erosion mechanisms can be divided into two main categories: surface erosion and bulk 
erosion [5, p. 180] [7, p. 5]. A schematic presentation of the two processes is shown in 
Figure 6. In surface erosion, the water diffusion step is slower than the degradation step, 
leading to gradual loss of material from the surface. The average molecular weight re-
mains relatively high for a long period of time. In bulk erosion, water penetrates the 
material rapidly, but polymer degradation is slow, leading to a gradual decrease in the 
average molecular weight with very low initial mass loss. Once a critical chain length is 
reached, the device disintegrates, resulting in rapid mass loss. In principle, a surface 
eroding system can provide a constant release rate if its surface area remains constant 
and drug diffusion is insignificant [7, p. 90].  
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Figure 6: A schematic illustration of the difference between bulk and surface erosion. 
Dashed line depicts the original dimensions of the eroded body. 
 
Due to their water-absorbing nature, hydrophilic polymers commonly exhibit bulk ero-
sion behavior, whereas more hydrophobic polymers favor surface erosion. Chemical 
structure of the polymer can be designed to facilitate chain cleavage through hydrolysis 
or specific enzymatic reactions by incorporating labile bonds, such as carbon-nitrogen 
bonds in polyurethanes or carbon-oxygen bonds in polyesters [7, p. 91]. Chain cleavage 
can be designed to occur in side-chains, crosslinks or the polymer backbone depending 
on the desired erosion kinetics [5, pp. 173–174]. Besides the chemical nature of the 
cleavable bonds, rates of polymer hydrolysis are also affected by factors such as mor-
phology and the nature of neighboring substituent groups [7, p. 92].   
 
Degradation behavior of the device is not only dictated by the choice of polymer mate-
rial, since the addition of any substances (excipients, active agents, etc.) into the matrix 
will change the degradation behavior, e.g., through catalysis or plasticization [5, p. 182]. 
Especially if hydrophilic molecules are incorporated in a bioerodible device, different 
osmotic mechanisms can play a significant role in system behavior and the resulting 
water uptake can cause matrix swelling, ruptures in the matrix, drug diffusion or con-
vective mass transfer [5, p. 180]. Furthermore, variations in environmental (in vitro) and 
physiological (in vivo) conditions can have significant effects on erosion kinetics [5, p. 
175].  
 
The majority of degradable DDS fall under three categories: injectable microparticles, 
preformed implants and injectable in-situ forming implants [5, pp. 171–172]. As the 
categories differ in size and structure, they also exhibit different release profiles. Micro-
particles, generally having a diameter of 10 to 100 µm, are characterized by large sur-
face areas compared to volume and so they often show release profiles with strong ini-
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tial burst release [5, pp. 186, 189]. The burst is followed by a local release rate mini-
mum and a shallow exponential increase and decrease. These fluctuations can be 
smoothed out by blending or with suitable matrix porosity [5, p. 189]. Preformed and 
in-situ formed implants are significantly larger in size than microparticles, so they natu-
rally exhibit a slower release and are usually functional over a longer period of time. For 
in-situ forming implants, a significant amount of drug may be released during the injec-
tion and hardening of the unhardened mixture [5, pp. 205–206].  
2.1.4.4 Osmosis Controlled Systems 
Water penetration and osmosis play a significant role in erosion and swelling controlled 
DDS and so they have already been briefly discussed in previous subsections. In such 
systems, osmosis, the diffusion of water, is a non-dominant step - its rate does not de-
termine drug release rate from the device to a large degree.  
 
An example of an osmosis controlled device is the osmotic pump (see Figure 7). It con-
sists of a tablet or capsule containing solid, water-soluble drug surrounded by a mem-
brane that is permeable to water but the drug cannot pass through it. At one side of the 
membrane, a small hole is drilled and as the system is placed in an aqueous solution, an 
osmotic pressure gradient arises. Water begins to penetrate the system through the 
membrane, dissolving the drug, which results in a flow of dissolved drug through the 
tiny orifice. As long as drug concentration in the core remains above its solubility, a 
constant release of drug from the device is maintained [5, pp. 21–22].  
 
 
Figure 7: A schematic presentation of the structure of a simple osmotic pump. 
 
More efficient versions of the osmotic pump feature additives that, upon introduction to 
water, exert a pressure to promote a more rapid flow of drug from the device [5, p. 22]. 
Different geometries and designs have been applied to improve the release profile by 
minimizing drug diffusion through the membrane, as few membranes are completely 
drug-impermeable [7, pp. 159–161].  
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Osmosis controlled monolithic devices have also been prepared and studied. The princi-
ple of this technique is embedding particulate dispersion of osmotically active drugs 
with low solubilities and diffusivities within a polymer matrix [7, pp. 162–163]. As the 
drug particles near the surface absorb water from the surroundings, a local pressure gra-
dient arises, eventually causing matrix rupture and drug release. This differs from ero-
sion-controlled release in the sense that ruptures are caused by osmotically induced 
stresses and not by polymer degradation.  
 
2.2 Silicone Elastomers 
This study focuses on the performance of silicone elastomer materials in controlled re-
lease drug delivery products. The goal of this section is to give a brief overview of the 
chemistry, practical applications and compounding of silicone elastomers.  
2.2.1 Siloxane Polymers – Classification and Synthesis 
Silicones (or polysiloxanes, siloxane polymers) are semi-organic polymers that have a 
backbone consisting of siloxane units [25, pp. 12–13]. Siloxane is a chemical group 
consisting of repeating silicon and oxygen atoms [25, p. 10]. A chemical structure of a 
siloxane group is presented in Figure 8.  The name siloxane is a portmanteau that comes 
from the words silicon, oxygen and alkane.  Silicon and oxygen are usually found in the 
nature in the form of silicate minerals. By mass, silicon and oxygen are the most abun-
dant elements in the earth’s crust [26] [25, p. 27].  
 
 
Figure 8: Structural formula of a siloxane group. 
 
Another important bond in silicones is the carbon-silicon bond between silicon atoms in 
the backbone and the connected substituent groups. Compounds of carbon and silicon, 
so-called organosilanes (or organosilicon compounds) are not found in the nature and 
they were first synthesized, in the late 19th century, using a Friedel-Crafts dialkylzinc 
reaction [25, p. 3].  
 
The process of silicone synthesis essentially begins with the reduction of silica (sand) 
into silicon at high temperatures [25, p. 367]. Elementary silicon is then reacted with an 
alkyl halide, most commonly methyl chloride that is first produced by reacting hydro-
chloric acid with methanol [25, pp. 382–384] [27]. The reaction between silicon and 
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methyl chloride occurs at elevated temperatures and features a copper catalyst, resulting 
in a mixture of silanes (𝑀𝑒𝑥𝑆𝑖𝐶𝑙𝑦 ) and byproducts. This so-called Direct Process,  
 
𝑥 𝑆𝑖 + 𝑦 𝐶𝐻3𝐶𝑙
𝑐𝑎𝑡.
→ 
∆
 𝑀𝑒2𝑆𝑖𝐶𝑙2 +𝑀𝑒𝑆𝑖𝐶𝑙3 +𝑀𝑒3𝑆𝑖𝐶𝑙 + 𝑀𝑒𝐻𝑆𝑖𝐶𝑙2   
+𝑜𝑡ℎ𝑒𝑟 𝑠𝑖𝑙𝑎𝑛𝑒𝑠 𝑎𝑛𝑑 𝑏𝑦𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠 ,  (2.12)  
 
developed by Rochow and Müller, is the most commercially significant route to organo-
silicon compounds [25, p. 383] [27]. Dimethyldichlorosilane, the species with the high-
est yield (over 50%), is then hydrolyzed to give a series of cyclic and linear oligomers 
and hydrochloric acid [27]. The hydrochloric acid can then be returned into the produc-
tion process of methyl chloride.  
 
The chosen polymerization reaction depends on the structure of the oligomers. Bifunc-
tional silanes are polymerized by condensation (step-growth polymerization) and cyclic 
oligosiloxanes by ring-opening polymerization [28, p. 1]. The chemical structure of the 
most common polymerization end-product, polydimethylsiloxane (PDMS), is shown in 
Figure 9.  
 
 
Figure 9: Structural formula of a trimethylsiloxy-terminated polydimethylsiloxane. 
The simple PDMS structure can be modified by the substitution of functional groups, 
creating unique property combinations. Properties and applications of silicones will be 
discussed in section 2.2.3.  
2.2.2 Vulcanization Methods 
Though the siloxane backbone is highly polar, its intermolecular interactions are largely 
hindered by the organic side groups. As a result, linear silicone polymers are mechani-
cally weak materials. To create strong and elastic materials, rubbers, they must be cross-
linked. The crosslinking reactions are made possible by tri- or tetrafunctional silanes 
containing groups that react under ionic conditions to form 𝑆𝑖 − 𝑂 crosslinks or by us-
ing organic parts of the polymer (vinyl or methyl groups and the hydrogen atom) to 
form organic crosslinks [25, p. 282].  
 
In practice, silicones are usually crosslinked using one of three methods: heat-sensitive 
radical cure, moisture cure at ambient temperature or transition metal catalyzed cure by 
hydrosilylation. [25, p. 282] [28, pp. 567–615]. Other more or less significant methods 
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include radiation cure, crosslinking via organic side chains and direct cure by a cata-
lyzed reaction of hydrosilane with a silanol [25, pp. 282–291] [28, p. 569].  
 
Heat-sensitive radical cure methods usually involve the use of peroxides that undergo 
thermal dissociation, resulting in radicals that act as crosslinking initiators. The radicals 
attack the carbon-hydrogen bonds in the side groups to form macroradicals that react 
between one another and create 𝐶 − 𝐶 crosslinks [25, pp. 287–288] [28, p. 569]. An 
example of such a reaction series with dibenzoyl peroxide is shown in equations  
 
 
(2.13), 
 
(2.14) 
 and 
 
 
(2.15). 
 
If unsaturated (vinyl) groups are present in the structure, low concentrations of di-alkyl- 
or hydroperoxides can be used to create a crosslinked material [28, pp. 570–571]. For a 
saturated, unmodified PDMS, aryloxy (or acyl) peroxides can be used, resulting in a 
randomly cross-linked matrix with ≡ 𝑆𝑖 − 𝐶𝐻2 − 𝐶𝐻2 − 𝑆𝑖 ≡ -type crosslinks [25, p. 
288] [28, p. 576]. In the former case, peroxide concentration has virtually no effect on 
the resulting crosslinking density, whereas in the latter, the relationship is more or less 
linear and higher amounts of peroxide as well as higher temperatures are needed than 
for unsaturated systems [25, p. 288] [28, pp. 571–572]. Largely used peroxides include 
2,4-dichlorobenzoyl peroxide for saturated systems and di-t-butyl peroxide and dicumyl 
peroxide for vinyl-containing systems [28, p. 577]. A post-curing cycle is commonly 
used with peroxide cured elastomers to enhance mechanical and thermal properties of 
the rubber and to remove volatile byproducts created in the crosslinking step [28, p. 
576].  
 
Room temperature vulcanization (RTV), so-called moisture cure, is based on condensa-
tion reactions of silanol groups in hydroxyl-terminated PDMS [25, pp. 282–284] [28, 
pp. 577–578]. Such a reaction can occur between the end groups of two polymer chains 
with no added substances, resulting in a completely inorganic backbone [28, p. 577]. 
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However, to form a three-dimensional network, multiple hydroxyl groups would be 
needed. In practice, it is more feasible to have the hydroxyl end groups react with tri- or 
tetrafunctional silanes (𝑅𝑆𝑖𝑋3 or 𝑅𝑆𝑖𝑋4) [25, p. 283] [28, p. 578]. This results in di- or 
trifunctional-terminated PDMS chains. Upon contact with moisture, these end groups 
undergo hydrolysis, yielding di- or trihydroxyl-terminated chains that react with each 
other to form a crosslinked matrix [28, p. 578].  Commonly used functional groups (𝑋) 
in the multifunctional silanes include acetoxy and alkoxy (e.g. methoxy) and oxime 
groups [28, pp. 578–585].   
 
Moisture cure systems are provided as either two-component or single component sys-
tems, depending on their application. In two component systems, one component con-
tains the silanes mixed with a metal carboxylate catalyst while the other component 
contains the PDMS polymer [28, p. 580]. In single component systems, the components 
are stored as a mixture and thus must be protected from exposure to moisture before 
use. Titanate catalysts are often used in single component systems [28, p. 583].  
 
Hydrosilylation cure is based on the reaction of hydridosilane (𝑆𝑖𝐻) with an unsaturated 
carbon-carbon bond, typically a silicon vinyl group (𝐶𝐻2 = 𝐶𝐻 − 𝑆𝑖 ≡) [28, p. 588]. 
The addition reaction is catalyzed by a noble metal, typically platinum. Addition to the 
carbon in β-position in the silicon vinyl group is usually favored [28, p. 591]. Since vi-
nyl groups can be incorporated in any part of the polymer chain, it is possible to design 
and create different types of networks by varying the substitution configuration of the 
polymer, resulting in property combinations unachievable with other curing methods 
[28, p. 601]. Drawbacks of this method include platinum-induced yellowing of the 
cured material, short shelf lifes at room temperature (after mixing) due to high catalyst 
reactivity and possible reactions of excess 𝑆𝑖𝐻 groups with water and moisture when 
cured in air [28, pp. 588–601]. On the other hand, the curing process creates no byprod-
ucts and only a small amount of catalyst is needed. Therefore, this vulcanization method 
is of interest for food and health industries [28, p. 601].  
2.2.3 Properties and Applications 
Silicone polymers, such as polydimethylsiloxane, have found a variety of applications 
as a direct result of their excellent high temperature and oxidative stability [28, pp. 216, 
230]. Silicones are also flexible at very low temperatures due to the exceptional flexibil-
ity of the polymer backbone. This makes them very useful for applications that require 
elasticity below ambient temperatures. Silicones have more flexible polymer chains 
than most organic polymers, firstly because the 𝑆𝑖 − 𝑂 bond is significantly longer 
(1.64 Å) than the 𝐶 − 𝐶 bond (1.53 Å) and secondly because only every other atom in a 
siloxane chain can have side groups that sterically hinder chain movement [28, pp. 216–
218].  
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Linear PDMS with moderate to high molecular weights show a glass transition near 
−123 °C and a linear dependence has been observed between Tg and molecular weight 
[28, pp. 218–219] [29, p. 500]. Substituent side groups can decrease Tg by increasing 
polymer free volume or increase Tg by decreasing chain mobility [28, p. 218]. Cross-
linked networks undergo glass transition at only slightly higher temperatures than their 
linear precursors [28, pp. 221–223]. In contrast to several other elastomers, the use of a 
reinforcing filler has virtually no effect on Tg for polydimethylsiloxanes [28, p. 222]. 
Though hardly relevant in the case of rubbers, it is worth mentioning that melting of 
linear crystalline PDMS occurs in temperatures as low as −60…−40 °C [28, pp. 225–
226]. Liquid crystalline silicone polymers can be prepared by side group substitution, 
yielding interesting property combinations [28, pp. 228–230]. 
 
The thermal stability of silicones originates from the strong 𝑆𝑖 − 𝑂 bonds (452 kJ/mol) 
that are very resistant to homolytic scission [27, p. 8]. Reported values of depolymeriza-
tion onset temperature in an inert atmosphere include 343 °C for hydroxyl-terminated 
linear PDMS to 350 °C for trimethylsilyl-terminated linear PDMS [28, pp. 230–233]. 
Another reported onset value for PDMS is around 400 °C [27, p. 12].  Oxidative reac-
tions in non-inert atmosphere will begin at lower temperatures and have been shown to 
start around 250 °C for PDMS [28, p. 233]. Phenylsilicones are known to remain stable 
at higher temperatures than methylsilicones [25, p. 257]. 
 
In general, safe temperature ranges for silicones in oxidative environments extend up to 
200 °C for long-term use and even up to 450 °C for short-term use [29, p. 438]. Oxida-
tion reactions cause degradation by attacking multiple different bonds, primarily the 
𝑆𝑖 − 𝐶 bonds, whereas depolymerization in an inert atmosphere occurs through 𝑆𝑖 − 𝑂 
bond scission [29, p. 495] [28, p. 230]. In contrast to depolymerization, oxidative deg-
radation tends to increase crosslinking density, making the material harder [25, p. 297]. 
Depolymerization of PDMS in an inert atmosphere results in a series of cyclic oligo-
mers, the most abundant being the cyclic trimer, followed by the tetramer and the larger 
oligomers in decreasing amounts [28, pp. 230–231].  
 
Unvulcanized silicone polymers are, in general, viscoelastic fluids. When crosslinked 
and filled with a reinforcing filler, they become strong and elastic materials. Mechanical 
(and electrical) properties of silicone rubbers are less dependent on temperature than 
those of organic rubbers [29, pp. 497–498]. This makes them the material of choice for 
applications with large temperature variations, even though many of their mechanical 
properties (strength, elongation at break, compression set, etc.) are surpassed by several 
organic rubbers at room temperature.  
 
Molecular weights of silicone elastomers (gums) used as rubber precursors are in the 
range of 300 000 – 700 000 g/mol for heat-vulcanizing elastomers and 10 000 – 100 000 
g/mol for RTV types [29, p. 388]. As a result, reported typical values (with no infor-
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mation provided on filler concentration) of tensile strength and elongation at break at 
room temperature include 10 MPa and 300–500% for heat vulcanized and 3 MPa and 
100–150% for RTV silicone rubbers [29, pp. 388, 502].  
 
Silicones are widely used as electrical insulators due to their low relative permittivity 
that is not affected by temperature to a large degree [25, p. 257]. In contrast to hydro-
carbon polymers, if faced with temperatures that result in oxidative degradation, the 
main degradation product, silica, is an excellent insulator by itself [25, p. 257].  
 
Silicones are generally very unreactive, except in highly acidic or basic environments 
[28, p. 315]. Silicone rubbers are highly resistant to oil and weathering (ozone, oxygen 
and UV radiation), but unmodified PDMS is easily swollen by solvents like gasoline 
and benzene [14, p. 257] [29, pp. 389–390, 502]. Silicone fluids are highly hydrophobic 
due to the organic side groups (e.g. methyl) that are typically pointed towards the mate-
rial surface [25, p. 257] [30]. They have a low surface tension and are capable of wet-
ting most surfaces [30].  
 
Typical applications of silicones include wire and cable insulation, gaskets, seals, tub-
ing, surgical implants, lubricants, coatings, molds and many household cleaning and 
personal care products [14, p. 372] [30]. They are used, e.g., in plastic, food, agricultur-
al, textile, pulp and paper, automotive, aviation, construction, electronics and medical 
industries [30]. Hydrophobicity of silicones is exploited to create moisture barriers in 
fabrics, waxes, sealants and potting materials [25, p. 257]. Purely silicone-based or 
chemically modified low-viscosity fluids are also used as release agents, surfactants, 
foam stabilizers and defoamers [25, p. 257]. The wetting characteristics of silicones are 
also beneficial in terms of biocompatibility [30]. Large-scale healthcare applications of 
silicones include tubing and membranes in extracorporeal equipment, coatings on medi-
cal devices and tools (such as catheters, needles and syringes), as well as orthopedic and 
aesthetic implants [2, pp. 1106–1116].  
2.2.4 Fillers for Silicone Rubbers 
In this subsection, the most commonly used fillers for silicone rubbers and their effects 
on material properties are discussed. Primarily of interest is the effect of silica on the 
diffusion of organic molecules in a PDMS network. A typical silicone rubber formula-
tion consists of silicone gum, fillers and curing agents [29, p. 400].  
2.2.4.1 Common Fillers 
Even when properly cross-linked, PDMS are relatively weak materials due to the lack of 
strong intermolecular forces [28, p. 570]. Therefore, reinforcing fillers are used in prac-
tically all applications that require mechanical strength. Silicas form clearly the most 
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common class of fillers used in silicone rubbers [29, p. 402]. Silica, silicon dioxide 
(SiO2), consists of a network of oxygen and silicon atoms, shown in Figure 10.  
 
 
Figure 10: Solid silicone dioxide is a three-dimensional network of atoms,  
where each silicon atom is bonded to four oxygen atoms. 
Silica exists in both amorphous and crystalline forms. Only amorphous silica is used as 
a filler in silicone elastomers [25, p. 462]. Though silica is chemically inert, crystalline 
silica particles with particle sizes ca. 1–5 µm pose health concerns as they can cause 
severe damage to the respiratory system if inhaled for prolonged periods of time [25, p. 
462].  
 
Two main types of synthetic, amorphous silica are used commercially: pyrogenic silica 
and precipitated silica. Pyrogenic (fumed) silica has a greater reinforcing effect of the 
two due to its smaller particle size and larger surface area (ca. 100–400 m2/g) [29, p. 
401] [31, p. 32]. A large surface area results in a large degree of intermolecular physical 
interactions. Consequently, fumed silica also causes the uncured elastomer to harden 
significantly during storage. It is produced by open flame combustion of chlorosilanes 
with a controlled amount of water [25, p. 311]. In this high temperature process, prima-
ry particles with sizes as small as 5–50 nm can be prepared [25, p. 311]. These particles 
coalesce to form (irreversible) aggregates and (reversible) agglomerates [31, p. 32].  
 
Precipitated silica has a somewhat lower reinforcing effect on the material, but it im-
proves high temperature stability in oxidative environments [29, p. 401].  It also causes 
less elastomer hardening during storage. Silica precipitation is commonly achieved by a 
condensation reaction that occurs when the pH of an aqueous sodium silicate solution is 
decreased [25, p. 311]. The final network structure and porosity of the product is deter-
mined by the choice of drying, washing and milling processes that follow [31, pp. 35–
38].  
  
To combat the elastomer hardening encountered with high filler loading, so-called struc-
ture control additives can be used [29, p. 403]. In contrast to silicone polymers, silica is 
 29 
highly polar. Therefore, silicas are often treated with organosilanes or cyclic polyorga-
nosiloxanes to change their surface chemistry, namely to increase their wettability by 
the polymer and consequently improve their dispersibility [29, p. 403]. In addition to 
silica, metal oxides and silicates as well as carbon black can be used as fillers for differ-
ent purposes such as pigmentation and stability enhancement [29, p. 402].  
2.2.4.2 Effect of Silica on Drug Diffusion 
Silicones have been used successfully as biomaterials for decades due to their biocom-
patibility and exceptional physico-chemical characteristics and they have also been ap-
plied to the field of controlled drug delivery. Therefore, the diffusion of pharmaceuticals 
through silicones and the effect of material composition on diffusion have been exten-
sively studied since the 1960s [24] [32–39]. Though a large number of variables will 
determine the overall effect of silica on drug permeation through a membrane, a general 
conclusion from the literature cited above is that the addition of silica into a silicone 
membrane decreases the permeation rate of pharmaceutical ingredients through the 
membrane.  
 
As discussed earlier in this chapter, the PDMS polymer is hydrophobic in nature and 
silica, on the other hand, is highly polar and hydrophilic. Depending on the chemical 
structure of a drug, it will have different interactions with the membrane polymer mole-
cules and filler particles. A highly polar drug will have low solubility in the polymer 
phase, but high affinity for the filler particles and will be distributed accordingly. After 
the drug (solution) comes into contact with the membrane, it will take a finite amount of 
time to saturate the filler aggregates with drug molecules, after which steady-state per-
meation is achieved [32]. The following observations support this explanation:  
 
1) The solubility of a drug in a membrane can be enhanced by the addition of fillers 
[16] [32].  
2) Filled systems show significantly longer “lag times”, but only a marginal de-
crease in steady-state diffusion rates [16] [32].  
3) The lag time was shown to have a linear dependency on the maximum adsorp-
tive capacity of filler, which is directly related to its available surface area [38].  
 
The lag time is defined by extrapolating the steady-state portion of a cumulative drug 
release graph, as shown is Figure 11. Its magnitude represents the relative amount of 
drug sorption on the filler [19].  
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Figure 11. The determination of lag time in a permeation experiment. 
 
Mazan and co-workers studied the dependence of progesterone steady-state diffusivity 
through PDMS membranes on silica content (hexamethyldisilazane-treated silica with a 
particle size of 10–100 nm) [33]. The dependence was relatively linear within the 0–10 
weight-% SiO2 concentration range. Measurement of a true concentration profile within 
the membrane at various times was accomplished with radioactively marked drug mole-
cules. A linear dependency of p-aminobenzoate transmission rate and PDMS membrane 
fumed silica content was discovered by Most [32]. In certain studies, silica has been 
applied directly to the drug solution (instead of the membrane) to see how much drug it 
retains [34] [36].  
 
Mazan et al. concluded that the negative effect of silica on steady-state release is caused 
by both silica-drug interactions and changes in the crosslink network [33]. Roseman 
rationalized that since all filler particles are saturated by drug molecules, the decrease in 
steady-state release cannot be attributed to adsorption of drug on the filler. He proposed 
that the small decrease can be explained simply by a decrease in polymer volume frac-
tion and possibly increased tortuosity [16]. Flynn and coworkers elaborated on this 
problem and reached a similar conclusion: the influence of an inert but adsorptive, im-
permeable filler (such as silica in a silicone rubber) on the steady-state flux can be ex-
plained by a reduction in effective diffusional area and an increase in diffusional path 
length [19, p. 492]. This implies that the relationship between filler concentration and 
drug permeation rate is at least close to linear.  
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2.3 Related Concepts of Elastomer Processing 
This section presents some principles and theory of elastomer processing closely related 
to this study: rubber compounding, mixing and mastication (or softening), extrusion and 
vulcanization. To limit the length of this section, the topic is covered very selectively.   
2.3.1 Compounding, Mixing and Mastication 
Compounding refers to the optimization of material properties by modifying a polymer 
material in terms of composition.  A rubber compound can contain several different 
polymers, filler systems, stabilizers, vulcanization agents, processing aids, pigments, 
oils, etc. [40, p. 417]. Rubber compounding is a science on its own and compound reci-
pes are valuable intellectual property for rubber product manufacturers. In this thesis, 
the terms compound and formulation are used interchangeably.   
 
Mastication, in the rubber industry, is a process of polymer breakdown caused by me-
chanical work [41, p. 96]. It is performed to reduce the viscosity of a high molecular 
weight elastomer prior to compounding, extrusion, molding or other shape-giving steps. 
Mastication is absolutely necessary for viscous natural rubber and helpful for synthetic 
rubbers [41, p. 96]. The resulting partly degraded material is softer and stickier, making 
the subsequent processing easier and allowing the incorporation of large concentration 
of fillers and additives. For silicone rubbers, breakdown of the polymer chains is not 
desired. The function of this softening step for silicones is to break some of the hydro-
gen bonds between filler particles and polymer chains that cause the material to harden 
during storage. Mixing and mastication of a rubber formulation can be performed with a 
closed chamber mixer (also known as an internal mixer), an open-roll mill or, less 
commonly, a continuous mixer [42, p. 517] [41, p. 96] [43].  
 
Internal (batch) mixers are very common in the rubber industry and can also be used for 
some thermoplastics and thermosets [41, p. 97]. They are advantageous in their ability 
to keep the mixed material at a constant temperature. Internal mixing is a more energy-
intensive process than mixing with an open-roll mill, and also significantly faster [41, p. 
99]. This is because mastication occurs over a much larger area than in open-roll mills. 
Internal mixers come in three main types: “Banbury”, “Shaw intermix” and “Baker-
Perkins shear-mix” [41, p. 98]. The Banbury type is the most common one. It consists 
of a cylindrical chamber that contains two counter-rotating rotors revolving at different 
speeds [41, pp. 97–99]. The special design of rotor geometry leads to shearing and 
movement of the material in several directions. The mixer includes a hopper through 
which material is introduced and an unloading door for removal of the mixed material. 
Material can be forced into the mixer with a mechanical ram. The chamber walls and 
rotors (if hollow) are often cooled with circulating water.  
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Open-roll mills consist of two (or more) rollers, steel cylinders that are placed horizon-
tally, parallel and close to one another [41, p. 97]. The rollers rotate in opposite direc-
tions and as material is fed on top of the rolls, it passes though the gap between the rolls, 
where mixing and mastication takes place. The front roll is usually set to revolve at a 
slightly slower speed than the back roll and the gap is adjusted to provide proper shear-
ing action [41, p. 97]. A schematic presentation of the structure of a two-roll mill is pre-
sented in Figure 12. As mastication takes place and enough rubber has been added, a 
band of rubber is formed on the front roll and material will accumulate as a “bank” 
above the gap. Compounding ingredients can then be fed into the bank. Several times 
during the process, the elastomer band is cut with a knife from the front roll and reintro-
duced to the mixer so that thorough mixing occurs.  
 
 
Figure 12: Schematic presentation of a two-roll mill. 
 
Continuous mixing is achieved with modified extruders that carry out both the mixing 
and extrusion steps of processing [43, pp. 175–176]. The barrel and screw have been 
fluted (grooved) at certain position along the barrel to increase the shearing action of the 
extruder. Higher shear rates are needed in order to break down particle agglomerates to 
achieve a good dispersion of fillers and other components of the compound.   
2.3.2 Elastomer Extrusion 
Extrusion is the most important polymer processing method [44, p. 15]. Extrusion pro-
cesses can be divided into continuous and discontinuous or batch type processes. Con-
tinuous processes involve the use of screw extruders and disk or drum extruders, where-
as discontinuous (cyclic) processes are run with ram extruders or reciprocating screw 
extruders [44, p. 23]. Continuous screw extruders for rubber processing are of interest in 
this study.  
 
Screw extruders can be classified into two groups according to the number of screws 
they contain: single-screw or multi-screw. Single-screw extruders form the most com-
mon class of extruders in the polymer industry. They are affordable, reliable, rugged 
 33 
and simple by their design [44, p. 24]. Twin-screw extruders are also used in a very 
large scale, mainly for specialty polymers or heat-sensitive polymers such as polyvinyl 
chloride and for materials that are hard to process, as they can provide better feeding 
and mixing as well as more accurate temperature control [44, p. 458]. A simplified 
structure of a single-screw extruder is shown in Figure 13, where the blue arrows depict 
the direction of material flow.  
 
 
Figure 13: Simplified structure of a single-screw extruder. 
 
Thermoplastics are usually fed into an extruder in the solid state and melted by electri-
cal barrel heaters and the heat created within the barrel by frictional forces – the extrud-
er has a plasticating function. Rubber extrusion differs from the extrusion of thermo-
plastics in the sense that the material is introduced into the extruder in a liquid, though 
highly viscous, state. This means that rubber extruders are essentially screw pumps that 
force a liquid material through a die. Both cold and hot feed extruders are used for rub-
bers, depending on the material [44, p. 27].  
 
Rubber extruders differ from thermoplastic extruders by their length, heating and cool-
ing systems, as well as by feed section and screw design [44, p. 27]. Rubber extruders 
are shorter than plasticating single-screw extruders [41, p. 24]. The viscosity of rubber 
is high compared to thermoplastics, leading to high frictional forces and excessive heat 
generation in long extruders. The typical L/D ratio (length/diameter of screw) is around 
5 for hot feed and between 15 and 20 for cold feed rubber extruders [44, p. 27]. Rubber 
extruders can be either heated or cooled down, depending on the material and its rheo-
logical and curing characteristics.  
 
The screw of a rubber extruder usually has a constant, large channel depth and a de-
creasing pitch, whereas a plasticating extruder usually has a constant pitch and a de-
creasing channel depth [44, p. 28]. These parameters are best explained by Figure 14. A 
deep channel results in decreased shearing and, consequently, reduced heat generation. 
Depending on the physical form of the material, different types of feed sections are 
found in rubber extruders. Rubbers are often fed into the extruder the form of strips, 
pellets or large lumps and sometimes also as powders [44, p. 27]. Depending on the 
material form, extruder feed sections can be equipped with rams or rolls to force the 
material into the barrel [44, p. 27].   
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Figure 14: A simple schematic presentation of channel depth, pitch and lead – im-
portant parameters of an extruder screw. 
 
The extruder die essentially determines the cross-sectional geometry and dimensions of 
an extrudate. With thermoplastics, controlled cooling of the extrudate is necessary for 
dimensional stability [41, p. 23].  With elastomers, some dimensional changes can occur 
after the die as a result of the shrinkage caused by vulcanization [45, p. 13]. Similarly to 
plastics extrusion, elastomer extrusion dies have to be designed to compensate for die 
swell. Die swell refers to the changes in geometry and dimensions of the extrudate as it 
exits the die caused by the viscoelastic behavior of the polymer material [45, pp. 108–
109]. The design of the die obviously depends on the final shape (rod, beam, pipe, film, 
sheet, filament etc.) of the product. Dies that are used for tube extrusion and wire coat-
ing or jacketing applications are discussed in the next section, as they are the ones rele-
vant to this thesis.  
2.3.3 Dies for Tube Extrusion and Extrusion Coating 
The extrusion of articles with hollow, circular cross-sections requires the use of a die 
that controls both the inner and outer diameters of the extrudate. This presents a prob-
lem: how to design the support for the inner part of a die (also known as the mandrel) 
without jeopardizing the homogeneity of the material flow? The extrusion of articles 
with hollow, circular cross-sections is usually accomplished with so-called mandrel 
support dies, screen pack dies, side-fed mandrel dies or spiral mandrel dies, the last one 
yielding the highest extrudate homogeneity [45, p. 153].  
 
Typically, some kinds of weld lines are formed when extruding hollow products, result-
ing from breaking the flow of material into two or more streams and then re-introducing 
these streams together before they exit the die [44, p. 447]. Weld lines are regions of 
lower mechanical strength and a well-designed die will minimize their appearance in the 
extrudate. A variety of methods for improving flow homogeneity at the end of a tube or 
pipe extrusion die have been developed [45, pp. 153–159].  
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While large pipes are typically extruded with longitudinally fed (in-line) dies, crosshead 
dies are more commonly used for small tubing [44, p. 446] [45, p. 159]. In a crosshead 
die, the direction of inward flow is perpendicular to the outward flow of material [44, p. 
447].  Besides tube extrusion, polymer coating of wires and cables is commonly per-
formed with crosshead dies [46, p. 469]. The wire to be coated is pulled through the die 
and and the molten plastic comes in contact with its surface and covers it.  
 
In this work, elastomeric tubing is coated with another elastomer. The process is, how-
ever, similar to the extrusion coating process of metallic wires. Wire coating extrusion 
processes can be divided into high pressure and low pressure extrusions (see Figure 15). 
In high pressure extrusion, the contact between the wire and the coating material occurs 
inside the die, whereas in low pressure extrusion, they come in contact after the wire has 
exited the die [44, p. 448]. High pressure extrusion yields better adhesion between the 
materials, while low pressure extrusion is a good alternative when it is important that 
the coating can be easily removed.  
 
  
(a) (b) 
Figure 15: Operating principles of wire coating dies of the low pressure (a) and high 
pressure (b) types. 
After extrusion, the coating is hardened by passing the extrudate through a cooling me-
dium (in the case of thermoplastics) or through a curing oven (in the case of rubbers) 
[41, p. 33]. Methods for continuous curing of extruded rubber products are discussed in 
the next subsection.  
2.3.4 Continuous Vulcanization of Extruded Products 
Continuous vulcanization of extruded rubber products can be achieved by various 
methods. Depending on the material, the continuous cure may or may not be sufficient. 
For heat-resistant fluorocarbon and silicone elastomers, for example, a post-cure cycle 
is needed to achieve complete cure and to eliminate peroxide residues [43, p. 191]. The 
continuous methods differ, for example, in attainable process speeds and in the amount 
of distortion to profile geometry caused by gravity and/or conveyor contact.  
 
The most common method of continuous vulcanization in profile extrusion is to pass the 
extrudate through a chamber of hot air [43, p. 165]. As the thermal conductivity of rub-
ber is very low, heat transfer into thick sections of a profile takes time.  Additional in-
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frared heaters or microwave emitters can be installed in the chamber to accelerate the 
heating process and to improve heat transfer. To achieve a desired degree of cure, air 
flow speed, extrudate movement speed, air temperatures and heater power inputs can be 
adjusted.  
 
Infrared or microwave systems can also be used independently. Infrared systems are 
used in the application of surface finishes to profiles and in the extrusion of certain sili-
cone rubber profiles and microwave systems are used with complex profile geometries 
when heat transfer becomes a problem and are best suitable for polar rubbers [43, p. 
166]. Even gamma irradiation cure can be used for some rubber compounds [43, p. 
167].   
 
One alternative method is the liquid medium cure, where the extrudate is passed typical-
ly through a steel tank containing molten salt and a conveyor to guide the extrudate 
through it [43, p. 166]. After passing through the bath, the extrudate is washed to re-
move salt residues. The used salts are often toxic so this method may raise health and 
environmental concerns. Another alternative is the fluid bed system (or fluidized bed) 
that consists of a bed of particles, typically glass beads, fluidized by blowing hot air 
through it [43, pp. 166–167]. The extrudate is passed through this bed of particles and 
subsequently cleaned.  
 
Quite similar methods have been used for continuous vulcanization of elastomer coated 
cables and wires. The vulcanization of cable coatings has been performed by passing the 
extrudate either through a hot steam tube, a hot air tube with the option of additional 
infrared heaters, a fluidized bed of glass beads, or a molten salt bath [43, p. 162].  
 
2.4 Experimental Design and Statistical Analysis 
This section discusses two concepts: designing experiments and statistically analyzing 
experimental data. In subsection 2.4.1 some basic principles of Design of Experiments 
(DoE) are discussed. The calculation, use and interpretation use of some relatively sim-
ple statistical parameters and tools relevant to this thesis are discussed in subsection 
2.4.2. These include correlation coefficient and the evaluation of statistical significance 
with p-values as well as theory behind linear regression models.  
2.4.1 Design of Experiments 
2.4.1.1 Introduction 
The scientific method involves the testing and refinement of hypotheses and theories 
through the acquisition of empirical evidence. This is achieved by conducting scientific 
studies. Scientific studies can be classified into observational studies and experiments 
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[47, p. 9]. In an observational study, a researcher passively observes a set of properties 
from a number of subjects, without purposefully altering their states in any way, where-
as in an experiment, a set of factors or independent variables are chosen, their levels are 
varied and controlled, and the resulting changes in a response or dependent variable are 
recorded [48, p. 15] [49, p. 1].   
 
An observational study can be prospective or retrospective, the retrospective type being 
the more common one [47, p. 10]. In a prospective study, a certain number of study sub-
jects are chosen, their initial conditions are recorded and they are observed for a given 
amount of time. A retrospective study tries to find explanations to the present states of a 
group of subjects by studying their histories. An example of a retrospective observa-
tional study would be finding risk factors for a disease by taking a random sample of 
citizens and studying their lifestyle habits, obesity and health history and assessing if the 
factors correlate with morbidity. Results from an experiment can provide more infor-
mation on causality and the data is easier to analyze since factors can be controlled and 
so-called confounding effects are less likely to occur [47, p. 10].  
 
Design of Experiments (DoE), pioneered by R.A. Fischer in the 1920s, is a systematic 
method for designing efficient experiments when the effects of multiple factors on a 
response must be assessed. Central to DoE are the principles of randomization, replica-
tion and the control of variation, e.g., through blocking [47, p. 5] [49, p. 12]. How an 
experiment is designed will affect the way the data from it can be statistically analyzed 
[47, p. 9] [49, p. 12].  
 
When planning a series of experiments, the first step is to recognize the problem that is 
to be studied and to explicitly state the questions to be answered by the study [49, p. 
14]. In this planning phase, a primary experimental plan is made. Before starting the 
experiment, it may be helpful to perform trial or practice runs to practice the experi-
mental technique, to ensure that measurement systems are working properly and test 
materials are consistent and to get an estimate of the experimental error [49, p. 20].  
 
Experimental study of a process often occurs in consecutive, iterative steps, namely 
screening, optimization and verification or confirmation studies [49, pp. 14–15]. The 
screening phase of a study involves a large range and variety of process parameters. Its 
goal is to experiment with the process to find important parameters and possibly discov-
er the nature (linear/curved) of their effects on the response and to give a primary idea 
about proper parameter values. In the optimization phase, the optimal parameter values 
are determined and statistical models, such as regression models and response surfaces 
are generated. The verification or confirmation step involves a re-run of the process 
with the optimal settings to create a reliable process [48, p. 15]. They serve to validate 
the conclusions of the study [49, p. 20].  
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2.4.1.2 Terminology 
The term controlled experiment refers to the ability to control the variables that affect a 
studied response. Obviously not all variables can be controlled, but nevertheless their 
effect on the response must be accounted for. The variables that cannot be controlled are 
called noise factors [48, p. 2]. Some noise factors cannot even be recognized or ob-
served – they are called lurking variables [48, p. 2]. Variables that are not controlled 
may confound the outcome of the study, leading to false conclusions about cause-effect 
relationships [48, p. 2]. The effect of uncontrollable variables can be managed by block-
ing and randomization.  
 
Applied combinations of factors are called treatments. When assigning experimental 
units to different treatments, it is advisable to use randomization. Randomization is used 
to reduce bias [48, p. 10]. By assigning the units randomly, systematic effects caused by 
all uncontrolled variables become part of the variance within each treatment group and 
are less likely to exhibit confounding effects [47, pp. 6, 10]. Furthermore, introducing a 
probabilistic element makes the statistical analyses valid [47, pp. 6, 10].  
 
Blocking is another way to deal with the effects of noise factors. When a variable is 
recognized and its values are known, but cannot be controlled, its effects can be can-
celled out by blocking [48, p. 10]. This means dividing the experimental units into 
blocks (i.e., groups) so that within each block, the variable is constant and then assign-
ing the treatments randomly within each block and analyzing the data from each block 
independently – for example, when studying the effect of a quenching temperature on 
the hardness of steel slabs with steel from three different production batches, it may be 
wise to create an individual block for each batch, if the batch-to-batch differences are 
not of primary interest [48, pp. 10, 13]. If a noise factor cannot be used for blocking, but 
its values can be measured, it is called a covariate [48, p. 11].  
 
Replication can be used to increase the precision of an experiment [47, p. 5]. Basically 
replicates are independent experimental runs performed with identical factor levels on 
different experimental units. A simple, illustrative example is presented by Tamhane 
[48, p. 6]: in a study where the effect of dough recipe on the taste of cookies is studied, 
replicates would be two batches of dough made independently according to the same 
recipe. Replicates are not the same thing as repeated measurements on a single experi-
mental unit, such as tasting of multiple cookies made from a single batch of dough. The 
latter is also referred to as pseudoreplication [47, p. 6].  
 
Balance of a design means that all treatments are assigned to an equal amount of exper-
imental units. The statistical analysis of a balanced design is straightforward, since each 
treatment is estimated with the same precision [47, p. 7]. The total error of an experi-
ment consists of systematic error and experimental error [48, p. 10]. Experimental error 
consists of replication error (caused by uncontrolled variables) and measurement error 
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(caused by inaccurate instruments and inspectors). Replication error is typically signifi-
cantly larger than measurement error [48, p. 10].  
2.4.1.3 Experimental Designs 
Different experimental designs are chosen depending on the phase of a study, the 
amount of variables and their nature and simply the amount of time and workforce 
available for the study. Four common designs are briefly discussed in this subsection. 
Design-specific methods of statistical analysis are not discussed here. Typically the 
analysis involves ANOVA (analysis of variance) and ANCOVA (analysis of covari-
ance) techniques. The latter is used, if covariates are introduced as new data at the anal-
ysis stage [48, p. 70].  
 
Completely Randomized Designs 
 
In a completely randomized design, all experimental units are assigned to treatments at 
random, without restrictions. Any heterogeneity among the units is controlled by ran-
domization [48, p. 70]. The simplest form of this design can be used to study the effects 
of a single factor on a response [48, p. 70]. It is often used when assigning, for example, 
human subjects to treatments in a comparative drug study. If two treatments are com-
pared, subjects can be assigned simply by flipping a coin. The experiment does not have 
to be balanced when randomization is used, i.e., unequal amounts of units may be as-
signed to different treatments without complicating the statistical analysis.  
 
Randomized Block Designs 
 
In a randomized block design, experimental units are divided into blocks and treatments 
are assigned at random within units in each block [48, p. 168]. The advantages of block-
ing are that the effects of selected noise factors can be cancelled out and the precision of 
the experiment can be enhanced, as previously discussed. Blocking also exposes the 
effects of these subgroups or categories on the response [48, p. 168].  In the steel 
quenching example presented earlier, even though blocking helps to remove the con-
founding effects of batch-to-batch differences, it also helps the experimenter to evaluate 
these differences.  
 
Factorial Designs 
 
If one is interested in the effects of multiple different factors on a response, factorial 
designs provide a systematic and statistically valid method for their evaluation [48, p. 
224]. In factorial designs, the factors are varied together, in a systematic way [49, p. 5]. 
Full factorial experiments study all factor level combinations, providing information not 
only on the independent effects (termed main effects) of these variables, but also on 
their combined effects, interactions [48, p. 224].  
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Factorial designs can be classified by the number of factors, 𝑓, and the number of dif-
ferent factor levels. For example, a 23 factorial experiment contains three factors, each 
having two different levels. Two-level factorial designs, 2𝑓, are commonly used in the 
screening phase of a study, when the effects of multiple factors are studied [48, p. 256]. 
When only a few factors are studied and the precise nature of the relationships (linear or 
curved) is of interest, three-level factorial designs are useful [48, p. 351]. An illustration 
of a 23 factorial design with an added center point is shown in Figure 16.  
 
 
Figure 16: Geometrical presentation of a 23 factorial design with a center point. 
To estimate response variance, replicate measurements are needed. However, replicat-
ing an entire design doubles the amount of experimental units and replicating only a 
fraction of the design will lead to design imbalance. Replicate measurements at the cen-
ter point can provide an estimate of the replication error without a large increase in the 
amount of experimental units or compromising the balance of the design [48, p. 279]. 
Center points can be added to a factorial design only if the studied factors are quantita-
tive [48, p. 279].  
 
As the amount of factors is increased, the total amount of treatments grows very large. 
While a 23 factorial design has only eight treatment combinations, for a 210 design, the 
total amount is 1024. Since it is often practically impossible to study so many combina-
tions, and many of the combinations are not likely to provide any useful information, 
fractional factorial designs, in contrast to full factorial designs, are typically used for 
experiments with a large number of factors [48, p. 300]. In fractional factorial designs, 
only a selected set of factor combinations are studied [49, p. 7].  
 
Response Surface Methods 
 
When factors are not constrained and can be varied independently of each other, re-
sponse surface methodology (RSM) can be used to optimize a response [48, p. 395]. 
The objective in RSM is to find the optimum response quickly by studying the response 
surface sequentially [49, p. 480]. For example, when trying to maximize the response, 
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the data from one experiment can show the direction for future experiments: the re-
sponse maximum is likely to be in the direction of steepest ascent [49, p. 480].  
 
The idea of RSM is to present the expected value of a response as a surface, which is a 
function of the factors [48, p. 396]. For three- or two-factor experiments, this also al-
lows an intelligible visual presentation for the model. Sometimes the factors cannot be 
varied independently, for example, when optimizing a material composition by chang-
ing the relative amounts of ingredients – the relative amount of one ingredient will una-
voidably affect the relative amounts of others. In this case, the standard RSM designs 
have to be modified accordingly [48, p. 414].  
 
To minimize the amount of treatment combinations that need to be studied, without sac-
rificing useful information, special variations of RSM designs have been designed. 
These include the central composite design and Box-Behnken design. So-called Taguchi 
designs are used to minimize response variation around a nominal target value [48, pp. 
419–422] [49, p. 22]. They are used for quality improvement, and are based on the idea 
of designing quality into products.  
2.4.2 Statistical Analysis 
2.4.2.1 Statistical Significance and Correlation 
When interpreting the results from an experiment with large amounts of multivariate 
data, it can be hard to make out what kinds of relationships actually exist between the 
variables without the use of statistical methods. Calculation of test statistics such as cor-
relation coefficients and the related p-values provides a clear-cut way to draw conclu-
sions about the relationships. Even though these statistics are usually calculated with 
computers, it is useful to take a brief look at their properties and formulas.  
 
Hypothesis testing is an important part of statistical inference. It involves presenting 
two contradictory claims about a variable and its effect on a response: a null hypothesis 
and an alternate hypothesis [50, p. 301]. The null hypothesis supports an “a priori” be-
lief about the variables, such as the inexistence of a relationship between them, in which 
case an alternate hypothesis would suggest that a certain relationship exists between the 
two variables.  For example, when conducting a study of the effects of a dietary habit on 
a disease, the null hypothesis might be that the habit is not correlated with the likelihood 
of catching the disease, in which case the alternate hypothesis would be that they are 
correlated. If the null hypothesis is to be rejected, a substantial amount of evidence 
against it must be found [50, pp. 301–302].  
 
Correlation coefficients are useful statistics in determining, whether a relationship exists 
between two variables. The commonly used one is the Pearson product-moment corre-
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lation coefficient. For two variables 𝑋 and 𝑌 of a sample, Pearson product-moment cor-
relation coefficient, 𝑅, can be calculated with the equation 
 
𝑅 =
∑ (𝑋𝑖−?̅?)(𝑌𝑖−?̅?)
𝑛
𝑖=1
√∑ (𝑋𝑖−?̅?
𝑛
𝑖=1 )
2√∑ (𝑌𝑖−?̅?)
2𝑛
𝑖=1
   −1 ≤ 𝑅 ≤ 1    (2.16)   
 
where n is the sample size, 𝑋𝑖 and 𝑌𝑖 are the individual observed values and ?̅? and ?̅? are 
the calculated sample means for these variables [50, pp. 508–510] [51]. The magnitude 
and sign of the coefficient show the strength and direction of linear correlation between 
the variables. This coefficient cannot detect a curvilinear relationship [50, p. 510] [51]. 
It is worth mentioning that strong apparent correlations can be obtained even for data 
with relatively high variance and small sample sizes and so the strength of evidence 
should be estimated by other parameters.   
 
A useful parameter in deciding whether the evidence is strong enough to reject a hy-
pothesis is the p-value. As expressed by Devore, the p-value is ”the probability, calcu-
lated assuming that the null hypothesis is true, of obtaining a value of the test statistic at 
least as contradictory to the null hypothesis as the value calculated from the available 
sample” [50, p. 329]. In other words, it indicates the likelihood that the null hypothesis 
falsely rejected. This is called Type I error in statistical inference. Type II error, on the 
other hand, occurs if the null hypothesis is not rejected when it is false [50, p. 304].  
 
To give a numerical value to the strength of evidence that is required from an experi-
ment, significance levels are used. Significance level, 𝛼, is the maximum probability of 
type I error allowed. If the p-value of a statistic, such as a correlation coefficient, calcu-
lated from the data is larger than the required significance level, rejection of the null 
hypothesis cannot be justified [50, p. 330]. If the p-value is smaller than the required 
significance level, the result is called statistically significant and the null hypothesis can 
be rejected [6, pp. 285–287]. Commonly used values of 𝛼 include 0.01, 0.05 and 0.10, 
depending on the seriousness of the possible type I error [50, pp. 307–308].  
2.4.2.2 Linear Regression Models 
Regression analysis is used to estimate relationships among variables. Simple linear 
regression can be used to model a linear relationship between a single predictor variable 
𝑥 and a single response variable 𝑦. The regression equation is of the form 
 
𝑦 = 𝛽0 + 𝛽1𝑥 + 𝜖 ,       (2.17) 
 
where 𝛽0 and 𝛽1 are called regression coefficients and 𝜖 a random error term [50, p. 
472]. The coefficients 𝛽0 and 𝛽1 have constant values, while 𝜖 is an independent, nor-
mally distributed random variable with an expected value of zero. [50, pp. 472, 477]. 
 43 
The coefficient 𝛽1 is the slope of the regression line and 𝛽0 is the intercept of the regres-
sion line with the 𝑦-axis. For a given value of 𝑥, all variance in 𝑦 is caused by the error 
term and so 𝑦 is also normally distributed.  
 
The regression coefficients are commonly estimated from the observed data with the 
least squares method. The principle of the least squares method is to find a regression 
line to which the average distance of all observed data points is minimal. For a set of 
data with 𝑛 pairs (𝑥𝑖, 𝑦𝑖) of observed data, this is achieved by minimizing the sum of 
squared vertical deviations from the regression line,  
 
 ∑ [𝑦 − (?̂?0 − ?̂?1𝑥)]
2𝑛
𝑖=1  ,      (2.18) 
 
where  ?̂?0 and ?̂?1 are the least square estimates of the regression coefficients [50, p. 
478]. Resulting formulas for the least square estimates are  
 
 
?̂?1 =
∑ (𝑥𝑖−?̅?)(𝑦𝑖−?̅?)
𝑛
𝑖=1
∑ (𝑥𝑖−?̅?)
𝑛
𝑖=1
2        (2.19)  
 
?̂?0 = ?̅? − ?̂?1?̅? ,       (2.20) 
 
where 𝑥𝑖 and 𝑦𝑖 are individual values and ?̅? and ?̅? the sample means of the two varia-
bles [50, p. 479]. Using these estimates, an estimated regression line, 
 
𝑦 = ?̂?0 + ?̂?1𝑥 ,       (2.21) 
 
can be created.  
 
Predicted values of the response are obtained by substituting values of x into the esti-
mated regression equation (2.21). Deviations of the actual observed response from the 
predicted values are called model residuals [50, p. 481]. It is assumed that the residuals 
are statistically independent and normally distributed [47, p. 22]. The sum of squared 
errors (or the sum of squared residuals),  
 
𝑆𝑆𝐸 = ∑ [𝑦 − (?̂?0 + ?̂?1𝑥𝑖)]
2𝑛
𝑖=1   
        = ∑ 𝑦𝑖
2𝑛
𝑖=1 − ?̂?0∑ 𝑦𝑖
𝑛
𝑖=1 − ?̂?1∑ 𝑥𝑖𝑦𝑖
𝑛
𝑖=1   ,   (2.22) 
 
gives an estimate to the total amount of variance of 𝑦 that the model is unable to explain 
[50, pp. 483–485].  Similarly, the total sum of squares,  
 
𝑆𝑆𝑇 = ∑ (𝑦𝑖 − ?̅?)
2𝑛
𝑖=1   ,      (2.23) 
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shows how much overall variance of 𝑦 is present in the data [50, p. 485].  Intuitively, 
the ratio of the two sums (𝑆𝑆𝐸/𝑆𝑆𝑇) gives an estimate to the relative amount of vari-
ance in y that the model is not able to explain.  
 
To quantify the predictive capability of a regression model, a parameter called coeffi-
cient of determination, 𝑅2, is typically used. It shows the relative amount of variance in 
𝑦 that the model is able to explain and is calculated as [48, p. 45] [50, p. 485] 
 
𝑅2 = 1 −
𝑆𝑆𝐸
𝑆𝑆𝑇
 .       (2.24) 
 
It shows how much of the total variance in 𝑦 the model is able to explain. Values close 
to one imply that the model has a high predictive capability. For example, if 𝑅2 = 0.90, 
the model can explain 90% of the observed variance of the response variable. For sim-
ple linear regression, using the least squares method, 𝑅2 is simply the square of the cor-
relation coefficient 𝑅 between the predicted and observed values of the response [50, p. 
510].  
 
When several predictor variables are present, but their relationships can be approximat-
ed as linear, the data can be analyzed with multiple linear regression (MLR). The gen-
eral additive MLR equation [50, p. 553],  
 
𝑦 = 𝛽0 + 𝛽1𝑥1 + 𝛽2𝑥2 +⋯+ 𝛽𝑘𝑥𝑘 + 𝜖 ,    (2.25) 
 
with 𝑘 predictor variables is essentially an extension of equation (2.17).  
 
Even though the predictor variables in equation (2.25) have to be independent, it is pos-
sible to study non-linear relationships with a regression model by substituting the 𝑥𝑖s 
with, for example, quadratic or cubic terms and interaction terms [49, p. 19] [50, pp. 
553–555]. Let us consider a set of data with two predictor variables, 𝑥1 and 𝑥2. If it 
seems that 𝑥2 has a quadratic relationship with the response and the effect of 𝑥1 on the 
response seems to depend on the value of 𝑥2, a regression model in the form of  
 
𝑦 = 𝛽0 + 𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽3𝑥2
2+𝛽4𝑥1𝑥2    (2.26) 
 
(with substitutions 𝑥3 = 𝑥2
2 and 𝑥4 = 𝑥1𝑥2) is likely to explain the response variance to 
a greater extent than a strictly linear model.  
 
The calculation of 𝑅2 follows essentially the same principles as for a simple linear re-
gression model, but the process is more complicated. As can be seen from equations 
(2.22) to (2.24), the value of 𝑅2 cannot decrease and usually will increase when new 
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predictor variables are added to the model. For multiple regression, a parameter called 
adjusted 𝑅2 is often used. It is better suited for the evaluation of an MLR model, be-
cause it will decrease if an introduced predictor does not significantly improve the mod-
el [50, p. 578]. This keeps the amount of predictors relatively low so that the model is 
easy to interpret while still giving good estimates for the response. The importance of 
choosing proper predictor variables was already discussed in subsection 2.4.1. A model 
with a reasonable amount of predictor variables that make practical sense is likely to be 
informative and easy to use.  
 
Adjusted 𝑅2 is calculated as  
 
𝑅𝑎𝑑𝑗
2 = 1 −
𝑀𝑆𝐸
𝑀𝑆𝑇
 ,       (2.27) 
 
where 𝑀𝑆𝐸 is the mean square error of the model and 𝑀𝑆𝑇 is the mean square total 
variance of the predictor [50, p. 578]. These are defined for a model with 𝑘 predictors as 
[50, p. 578]  
 
𝑀𝑆𝐸 =
𝑆𝑆𝐸
𝑛−𝑘−1
    and       (2.28) 
 
𝑀𝑆𝑇 =
𝑆𝑆𝑇
𝑛−1
 .        (2.29) 
  
The calculation of 𝑆𝑆𝐸 and 𝑆𝑆𝑇 for MLR is similar to that done for simple linear re-
gression (see equations (2.22) and (2.23)), but, a larger number of terms will obviously 
be included in the 𝑆𝑆𝑇 equation. 
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3 MATERIALS AND METHODS 
3.1 Products 
A short description of the two products under study is given in this section. From a drug 
release perspective, they can be both viewed as cylindrical, diffusion controlled CDD 
devices. Product A releases a single active substance, whereas Product B releases two. 
Both products have a circular cross-section and they are structured in the following 
manner. The products feature drug cores, reservoirs, consisting of a drug substance 
bound to an elastomer material. The core is saturated with drug and the viscosity of the 
core elastomer is relatively low compared to that of the membrane that surrounds the 
core. Product B is of purely of the reservoir type as the drug core is fully surrounded by 
the membrane, whereas Product A features open ends that exhibit monolithic-type re-
lease.  
 
The structure of Product A is presented in Figure 17. The cylindrical drug-elastomer 
core is coated with an elastomer membrane and the resulting rod-like structure is 
mounted on a polyethylene body. The surface area of the open ends is small compared 
to the dimensions of the product. During use, the portion of release that occurs through 
the ends decreases, as the ends become depleted of drug and the average diffusional 
path increases in length.  
 
 
Figure 17: A rough schematic presentation of Product A geometry. The innermost part 
is the polyethylene body, the central part (drawn in dark blue) is the drug core and the 
outermost part is the elastomer membrane.  
The structure of Product B is slightly more complex, as it features two different drug-
elastomer core sections and additional “dummy” sections that do not contain an API. 
Nevertheless, it behaves somewhat similarly to Product A from a drug release perspec-
tive. In terms of cross-sectional diameter, Product B is roughly twice as large as Product 
A, but its membrane thickness is similar to that of Product A.  
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3.2 Materials and Specimen Preparation 
The rate-controlling outer membranes of both products are made of silica-filled polydi-
methylsiloxane (PDMS) elastomers. Previous studies have shown that increasing the 
amount of fumed silica in the membrane material results in decreased API release rate 
from the product. This study seeks to further quantify the effect within a defined range 
of manufacturing parameters and product dimensions in order to optimize the material 
composition.  
 
For the purposes of this study, specimens of both products were manufactured using 
five different membrane materials. Two of these materials were from established pro-
viders (Providers 1 and 2), and three were from a new provider (Provider 3). The new 
materials have all slightly different silica contents. The materials are presented in great-
er detail in the following sections. In contrast to normal product manufacturing, the 
specimens were not sterilized. This should be taken into account when comparing the 
results to ones obtained for sterilized units.  
3.2.1 Experimental Design 
In this experiment, drug release rate is the response variable and membrane thick-
ness and membrane material silica content are the two factors that are varied. Other 
process factors are either controlled by keeping them constant (or within certain toler-
ances) or assumed to have no direct or confounded effects to the response, based on 
earlier experience and research on the process. A schematic presentation of the experi-
mental design for the materials from the new provider along with the number of speci-
mens in each combination is shown in Figure 18.  
 
Figure 18: A graph presenting the amount of release rate specimens prepared for each 
factor level combination with Provider 3 membrane materials. 
This is essentially a simple 22 full factorial design with an additional centerpoint at the 
nominal membrane thickness and medium silica content. Having a centerpoint, this de-
sign can also give information about possible higher-order (curved) interactions and the 
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high amount of replicates at the centerpoint allows a good estimation of replication er-
ror. A similar design is applied for the study of both products. For the materials from 
providers 1 and 2, only two parallel runs were made for each membrane thickness. The 
principle of randomization was not applied in this work. It was assumed, according to 
earlier experience, that the analysis order of specimens could not have any significant 
effect on the results and it would have been highly impractical to apply randomization 
to the specimen manufacturing process.  
 
It was estimated, based on earlier research on the process, that because the ranges of the 
two factors are narrow, the resulting differences in the response would be small. There-
fore, it was important to have several parallel experimental points for each material-
dimension combination in order to achieve statistically significant results.  It was also 
known that slightly different results are obtained, systematically, with different shaking 
water baths in the release rate analysis (see subsection 3.3.6). Therefore, it was equally 
important that all specimens within a test series could be fit into a single water bath.  
 
Control of bath-to-bath variation by blocking was also considered, but eventually the 
single-bath option was chosen to save analytical resources. This limited the total speci-
men amounts to 32 for Product A and 34 for Product B. To reduce the specimen count 
by two, it was decided that the materials from Provider 1 would not be analyzed for 
Product A at nominal membrane thickness, since such specimens had already been ana-
lyzed in previous studies. The small response variation caused by using a different water 
bath is hardly significant in terms of general evaluation of product performance, but 
since very small changes to the response are expected in this study, it is important to 
exclude all unwanted confounding effects.  
3.2.2 Product A Specimen Preparation 
The preparation process of Product A specimens consisted of several steps: preparation 
of a drug-elastomer mixture, extrusion of drug core, coating extrusion of drug core, 
post-curing, cutting and product assembly. Specimens with varying coating membrane 
thicknesses and coating materials were prepared.  Only the release rate specimens re-
quired product assembly. In addition, membrane tubes were extruded for material char-
acterization.  
 
Temperatures were maintained at moderate levels during the extrusion and post-curing 
processes to ensure that no significant degradation of the API would occur. Safe tem-
perature ranges were chosen according to earlier research within the company. Suffi-
cient curing was confirmed by comparing the chosen process temperatures to the results 
of rheological tests (see subsection 3.3.1), by determining the amounts of low molecular 
weight species in the membrane tubes (see subsection 3.3.3) and by mechanical tests 
(see subsection 3.3.4).  
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3.2.2.1 Preparation of Drug-Elastomer Mixture 
The specimen preparation process began with mixing of the drug core ingredients: un-
filled, heat-vulcanizing silicone elastomer and micronized API-1 powder. The target 
API concentration was 65 percent by weight. The ingredients were weighed with a pre-
cision balance (PG4002-S Delta-Range®, Mettler Toledo, Switzerland). The mixing 
was performed with an internal mixer with two intermeshing rotors (Poly-Lab System: 
Rheocord/Rheomix 300p, Thermo Fischer Scientific, Karlsruhe, Germany). The ingre-
dients were mixed in two batches due to small chamber size of the mixer. 
 
The mixing began with feeding of the unfilled elastomer into the mixing chamber. 
Then, the API powder was slowly added (manually, using a steel spoon) and forced into 
the chamber with a mechanical ram. When all the ingredients had been added, the mix-
ing was continued for 10 to 15 minutes. Since the batch size was very small and used 
mixing speeds rather low, no heat build-up was expected and thus no cooling device 
was used with the mixer. Higher mixing speeds (20 to 40 rpm) were used for the second 
than the first batch (roughly 20 rpm), but since the two batches would be later com-
bined, no overall specimen-to-specimen variation can result from differences in mixing 
parameters.  
 
After removal from the mixer chamber, both mixtures still contained some visible pock-
ets of API in powder form. A two-roll mill (Polymix 110 P, Schwabenthan Maschinen, 
Berlin, Germany) was used to combine and to further homogenize the drug-elastomer 
mixtures. When the combined mixture seemed completely homogeneous, ten repre-
sentative samples, each weighing approximately 0.3 g, were taken from the mixture for 
homogeneity analysis (see subsection 3.3.2) . The remaining mixture was placed in a 
sealable polyethylene bag and stored in a refrigerator until its extrusion.  
3.2.2.2 Extrusion of Drug Core 
Extrusion of the drug core was performed using a laboratory-scale single-screw extruder 
(LAB extruder, Mantechno Oy, Raisio, Finland) and a conveyor oven (Insrumentti Mat-
tila Oy, Nousiainen, Finland). The extruder screw temperature was maintained at room 
temperature using a circulating water cooler (UWK 45, Haake, Karlsruhe, Germany). 
Prior to extrusion, the drug-elastomer mixture was softened using a two-roll mill 
(Polymix 110 P, Schwabenthan Maschinen, Berlin, Germany).  
 
A simple longitudinally fed mandrel-support die was used for the extrusion of the hol-
low drug core tube. Proper conveyor oven temperature and conveying speeds were cho-
sen according to earlier research within the company to allow sufficient cross-linking 
without API degradation and the extruder screw speeds were adjusted accordingly.  
 
During extrusion, the outer diameter (OD) of the extrudate was continuously monitored 
with an in-line dimension measurement device, an optical micrometer (Lasermike 182-
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11, Lasermike Inc., Dayton, Ohio, USA). The inner diameter (ID) was checked manual-
ly with plug gauges at the beginning of the extrusion process and at the end of each ex-
truded drug core coil. In addition, a weight control sample was taken from each extrud-
ed coil to verify that the membrane thickness was within normal core extrusion specifi-
cation limits. The coils were stored at room temperature in a polyethylene bag separated 
with sheets of baking release paper.   
3.2.2.3 Coating and Membrane Extrusion and Post-Curing 
In contrast to other phases of the specimen preparation process, in this phase variation 
was intentionally induced to the specimens. Five different coating materials were used 
and three different coating thicknesses were applied according to the experimental de-
sign shown in the beginning of this chapter.  
 
Materials 
Compositions of the Provider 3 elastomer base batches are shown in Table 2. PA-fluid 
(PA = Prosessing Aide) is a low molecular weight siloxane fluid that reduces the viscos-
ity of the material and it is used to coat the fumed silica during the compounding pro-
cess.  
 
Table 2: Compositions of the Provider 3 materials elastomer bases used in this study.  
Batch Silicone gum 
 (weight-%) 
PA-fluid 
 (weight-%) 
Silica  
(weight-%) 
Low silica 53.0 12.5 34.5 
Medium silica 52.4 12.5 35.1 
High silica 51.8 12.5 35.7 
 
All membrane materials were known to contain significant amounts of amorphous silica 
filler. The silica used in the Provider 3 batches was fumed silica with a known surface 
area and no surface treatment prior to treatment with PA-fluid. No specific information 
on the type of silica was available for Provider 1 and 2 materials.  
 
Provider 1 and 2 materials already contained a crosslinking agent, while the materials 
from Provider 3 did not, so the first step was the addition of peroxide to the three new 
materials.  The used peroxide paste was a mixture of 50 w-% silicone oil and 50 w-% 
2,4-dichlorobenzoyl peroxide (Azko Nobel Chemicals, Amsterdam, Netherlands). The 
materials were weighed with a precision balance (PG5002-S DeltaRange®, Mettler To-
ledo, Switzerland) and mixed with a two-roll mill (Polymix 110 P, Schwabenthan Mas-
chinen, Berlin, Germany). The weighed amounts and calculated peroxide contents are 
presented in Table 3. 
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Table 3: Weighed amounts of Provider 3 elastomer base and peroxide paste and the  
resulting peroxide contents for the elastomers. 
Elastomer 
batch 
Amount of  
elastomer base (g) 
Amount of per-
oxide paste (g) 
Resulting peroxide 
content (w-%) 
Low silica 603.73 6.64 0.544 
Medium silica 605.91 6.65 0.543 
High silica 599.31 6.59 0.544 
 
The mixing procedure consisted of softening the elastomer base and turning it into a 
form of a sheet, weighing the elastomer sheet, weighing the peroxide paste, applying the 
peroxide paste on the elastomer sheet, folding the sheet and finally feeding the folded 
sheet to the two-roll mill and mixing the constituents. The mixed elastomers were stored 
in a refrigerator in polyethylene bags. All coating materials were softened with the two-
roll mill before the rheological analyses and the start of the extrusion.  
 
Extrusion process 
Coating extrusion and membrane tube extrusion were accomplished with a laboratory 
scale single-screw extruder, consisting of a measurement and control unit (Rheocord 
9000, Haake, Karlsruhe, Germany) and an extrusion unit (Rheomex 102, Haake, Karls-
ruhe, Germany). A circulating water cooler (UWK 45, Haake, Karlsruhe, Germany) was 
used to maintain the extruder screw at room temperature. A crosshead die was used so 
the drug core could be fed inside the extruded coating membrane (see subsection 2.3.3). 
After leaving the die, the extrudate passed through a shock oven and a conveyor oven 
(Instrumentti Mattila Oy, Nousiainen, Finland).  The outer diameter (OD) of the extru-
date was continuously measured with an optical micrometer (Lasermike 182-11, La-
sermike Inc., Dayton, Ohio, USA), as it exited the conveyor oven. An overhead view 
scheme of the process is shown in Figure 19.  
 
 
Figure 19: Schematic presentation of the coating extrusion process  
for Product A (an overhead view). 
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A shock oven was used in the process to cure the surface of the extrudate so it would 
not stick to the belt of the conveyor oven. The extrudate would hang freely after leaving 
the die until it reached the conveyor oven. According to practical experience, it was 
crucial not to apply any significant axial tensile stress to the uncured extrudate, as it 
might lead to unwanted dimensional changes of both the coating and the drug core. Care 
was taken to keep the length of this extrudate loop, the “tightness” of the extrudate, rela-
tively constant to minimize any resulting specimen-to-specimen variation.  
 
For each coated drug core batch, a batch of membrane tube was extruded with identical 
parameters. Oven temperatures, conveyor speeds, pressures at the die as well as screw 
speeds and screw temperatures were measured and monitored during the process. Varia-
tions in screw speeds between runs were necessary to achieve the desired OD values 
since perfect die combinations for achieving the target dimensions were not available. 
Luckily, the resulting variations in the pressure values at the die were small, with pres-
sure values between 100 and 120 bars, so large variations in extrudate properties are not 
expected.  
 
The extruded coils were post-cured in a convection furnace (ULE 500, Memmert GmbH 
& Co. KG, Germany). The post-curing temperatures and times were identical for all 
extruded batches, both the membrane tubes and the coated drug cores. The color of the 
coated drug cores changed from clear white to pale yellow during the post-curing pro-
cess. The post-cured extrudates were stored in room temperature in polyethylene bags 
and separated with sheets of baking release paper.  
3.2.2.4 Assembly, Final Inspection and Dimension Measurements 
Before assembly could be performed, the coated drug cores had to be cut into cylinders 
of a specific length. The cutting was performed manually, with a scalpel. The specimens 
were cut as perpendicularly to the longitudinal axis as possible, trying to avoid any cur-
vature.  Before assembly, the cylinders were examined and their lengths verified with an 
optical microscope (Quadra-Chek 300, Metronics, Bedford, New Hampshire, USA). 
Additionally, their cross-sectional diameters and membrane thicknesses were measured 
and recorded.  
 
By examining the cylinder cross-sections, it was noted that in some coated cores, the 
coating membrane was not of uniform thickness as the thickest spot of the membrane 
was up to 40% thicker than the thinnest spot. As a consequence, several cylinders were 
cut from different parts of the extrudates and the ones that exhibited the highest concen-
tricities were chosen for the assembly.  
 
To make the manual assembly of specimens possible, each cylinder was swollen in cy-
clohexane (analytical grade, Merck KGaA, Darmstadt, Germany) for 38–48 seconds. 
The cylinders with thick membranes were swollen for a slightly longer time than the 
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ones with thin membranes. Instantly after swelling, the cylinders were pushed onto solid 
polyethylene bodies that had a diameter close to the inner diameter of the drug core. The 
solvent was allowed to evaporate for a minimum of 2.5 hours, after which the speci-
mens were once again examined with the microscope to see if any significant defor-
mation had happened to the cylinder and to which extent the lengths of the cylinders 
differed from the ones measured before the assembly. The results are discussed in sec-
tion 4.7.  
3.2.3 Product B Specimen Preparation 
As Product B contains two different drug core segments, the specimen preparation pro-
cess differs from the one used for Product A. Instead of using coating extrusion, the 
membrane tubes and different core sections were manufactured separately and assem-
bled later into complete specimens. Membrane materials used for Product B were the 
same as for Product A. Materials from Providers 1 and 2 were from different batches in 
products A and B, but materials from Provider 3 were from the same batches in both 
products.  
3.2.3.1 Preparation of Drug Cores 
Product B drug cores were prepared somewhat similarly to Product A drug cores. Both 
cores consisted of silicone polymer and micronized API powder. Target API concentra-
tion for API-1 core was 50 weight-percent and for API-2 core, ten weight-percent. Mix-
ing was performed with internal batch mixers. Representative samples were taken from 
the API-1 mixture for API Content and Homogeneity analysis (see section 3.3.2). Ho-
mogeneity of the API-2 mixture was evaluated visually. Processing temperatures were 
once again chosen according to earlier research and experience within the company, to 
ensure that no significant degradation of the API would occur.  
3.2.3.2 Extrusion of Elastomer Core 
Extrusion of Product B elastomer core, “dummy core”, was performed with the same 
equipment as the extrusion of Product A membrane tubes and coated cores (see section 
3.2.2.3 and Figure 19). Rotating speed of the extruder screw was between 25 and 32 
rpm and the measured pressure at the die was approximately 5 bars. Shock oven tem-
perature was 250 ± 5 °C and conveyor oven temperature was 200 ± 5 °C. Only Provider 
2 elastomer was used for the elastomer core. The extrudate was post-cured at 200 ± 5 °C 
for 3 hours and stored in a polyethylene bag after it had cooled to room temperature.   
3.2.3.3 Extrusion of Membrane Tubing 
Prior to membrane extrusion, peroxide was mixed to two Provider 3 batches. Weighing 
and mixing was performed with the same devices and in the same way as in the Product 
A process. There was no need to mix peroxide to the medium silica elastomer base 
batch, since enough mixture was left over from the Product A process. Weighed 
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amounts and resulting peroxide contents are shown in Table 4, including the medium 
silica batch mixed previously. The mixed batches were studied with the rheometer, as 
was done in the Product A process. The mixed (and analyzed) materials were stored in a 
refrigerator in polyethylene bags until extrusion.   
 
Table 4: Addition of peroxide to Provider 3 elastomer batches used in Product B mem-
brane extrusion. Weighed amounts and resulting peroxide contents.  
Elastomer 
Batch 
Amount of   
Elastomer Base (g) 
Amount of per-
oxide paste (g) 
Resulting peroxide 
content (w-%) 
Low silica 623.65 6.87 0.545 
High silica 607.49 6.68 0.544 
Med. silica 605.91 6.65 0.543 
 
Product B membrane tubing was extruded using the same equipment as with the elas-
tomer core, with the exception of using two different extruders. This was due to an un-
expected malfunction of the Haake extruder. As a result, some variation occurred in 
process parameters, even though the extruders were similar in size and screw design. 
Shock oven temperatures and conveyor oven temperatures were varied between batches, 
to compensate for differences in conveyor oven speeds. Five different materials were 
used and three membrane thicknesses were sought, according to the experimental design 
shown in the beginning of this chapter.  
3.2.3.4 Assembly, Inspection and Dimension Measurements 
Product B specimens were assembled with a product-specific assembly process that 
consisted of inserting the drug and elastomer cores of specific lengths within the mem-
brane tube and closing the ends of the tube using a silicone adhesive. Once the adhesive 
had cured, the integrity of the membrane and the adhesive seals was verified visually 
and with a microscope. Small voids were observed in some of the API-2 sections and 
their approximate sizes and positions were recorded. The outer diameters at different 
specimen sections were measured with an optical microscope (Quadra-Chek 300, Met-
ronics, Bedford, New Hampshire, USA) and recorded.  
3.3 Methods of Analysis 
Several different analyses were performed for the purposes of this study. Rheological 
and mechanical analyses were conducted to ensure that the materials from different pro-
viders would not differ markedly from each other in terms of mechanical strength of 
processability and to see if small variations in material silica content would results in 
any noticeable changes in these properties. The drug content and homogeneity of the 
reservoir was evaluated by analyzing the prepared drug-elastomer mixtures. The 
amounts of oligomers in cured elastomer membranes were analyzed to take into account 
the effect of oligomers on drug diffusion through the membrane. In addition, filler con-
centrations of the elastomers were evaluated by thermogravimetry. Finally, the main 
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response variable of the present study, the drug release rate, was analyzed for both 
products.  
3.3.1 Rheometry 
To ensure material quality, rheological properties and curing characteristics of all the 
used coating membrane materials were analyzed with a dynamic mechanical rheological 
tester (RPA 2000, Alpha Technologies, Akron, Ohio, USA). The device is essentially a 
rotating die rheometer designed for analyzing elastomers and mixed rubbers. In con-
trolled conditions, it exhibits an oscillating deformation to a specimen and records the 
required torque. Using the recorded data, specimen dimensions and geometry, it calcu-
lates rheological quantities such as the material’s storage and loss moduli and complex 
viscosity. The test parameters are shown in Table 5. 
 
Table 5: Parameters of the rheological analyses conducted for membrane materials. 
 
The tests were conducted prior to starting the coating extrusion process, when the mate-
rials already contained a curing agent and had been softened and homogenized with a 
two-roll mill (see subsection 3.2.2.3). For each test, a minimum of 4.5 cm3 of the mate-
rial to be tested was placed between two polyester sheets and inserted between the rhe-
ometer heads and the test was started.  
 
 
Figure 20: Photograph of a curing test specimen after the test. 
Parameter Viscosity measurement Curing analysis 
Temperature 30 °C 115 °C 
Oscillation frequencies 0.1 Hz; 2.0 Hz; 20 Hz 1.7 Hz 
Oscillation amplitude 0.5 ° 0.5 ° 
Die Biconical Biconical 
Sample volume 4.5 cm3 4.5 cm3 
Test duration (irrelevant) 
5 measurements per frequency 
5 minutes 
No. of parallel samples 1 1 
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Figure 20 shows a curing specimen that has been tested and illustrates the complex die 
geometry. It can also be seen that the uncured excess material at the perimeter remains 
opaque while the cured material has become more transparent.  The obtained results are 
discussed in Section 4.1.  
3.3.2 API Content and Homogeneity 
A homogeneity analysis of the drug-elastomer mixture was conducted prior to drug core 
extrusion using high performance liquid chromatography (HPLC). This analysis helps 
to rule out any response variation caused by differences in the API content between 
specimens.  As discussed in Sections 3.2.2.1 and 3.2.3.1, several samples were taken 
from the API-1 drug-elastomer mixtures after mixing. The analysis was performed ac-
cording to an internal guide of Bayer.  
 
The test begins with quantitative extraction of the API from the drug-elastomer mixture 
with a suitable solvent and preparation of API reference solutions. The solutions are 
further diluted with the mobile phase (acetonitrile/water) to predetermined volumes.  
Prior to analysis, system accuracy is ensured by performing multiple HPLC runs with 
reference solutions and evaluating the relative standard deviation of the test series. The 
sample and the reference are injected and the areas of the resulting chromatogram peaks 
are used to calculate the API content of the drug-elastomer mixture, taking into account 
the purity of the reference substance. The analysis was performed using an Agilent 
Technologies 1200 series HPLC apparatus with a reversed-phase column, UV-detector 
and automatic sample injection. The results of this analysis are discussed in section 4.2. 
3.3.3 Extractable Oligomers 
Literature and previous research within the company showed that low molecular weight 
fractions in the polymer material affect its permeability to drug molecules. This is why 
the amounts of PDMS oligomers were analyzed from the membrane tubes.  The analysis 
began by weighing a glass vial and a sample of membrane tubing with an analytical 
balance. Then, n-hexane was added to the vial and the vial was shaken in room tempera-
ture with a planar shaker for 16–20 hours, closed with a cap that had a Teflon coating 
(septum) at the inner surface. After shaking, the extraction solution was removed and 
the vial, containing the sample, was rinsed with n-hexane. The solvent was removed and 
the vial and sample were dried in a vacuum in 40 °C for one hour and cooled at ambient 
temperature and pressure for one hour. Finally, the vial, containing the sample, was 
weighed and the change in sample mass was calculated.  
3.3.4 Mechanical Tests 
For reasons related to product use and the manufacturing process, certain mechanical 
properties are required from the membrane material. Silica was known to influence the 
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mechanical properties of the materials studied, so simple tensile tests were conducted to 
see if the small variations in filler content would have any discernible effect.  
 
In the case of Product A, tests were performed on both the membrane tubes and the 
coated drug cores, whereas for Product B, only the membrane tubes were tested. Five 
specimens, each 12 cm in length, were cut from each batch and their diameters and 
membrane thicknesses measured from the ends of the specimens with an optical micro-
scope (Metronics, Quarda-Chek 300, Bedford, New Hampshire, USA) in the case of 
Product B and with a video coordinate measurement device (Nexiv VMR-3020, Nikon 
Corporation, Tokyo, Japan) in the case of Product A. To ensure data comparability, the 
influence of measurement device on the results was evaluated by performing an identi-
cal series of dimension measurements with both devices. No significant systematic error 
was found.   
 
The tests were conducted with a universal mechanical testing machine (5565, Instron 
Ltd., Buckinghamshire, England) and a long-travel extensometer (2603-080, Instron 
Ltd., Buckinghamshire, England) with a gage length of 25 mm. Pneumatic grips with 
rubber-coated faces were used to fasten the specimens into the machine. A testing speed 
of 500 mm/min was used and the tensile test was run until specimen failure. Test results 
are discussed in section 4.4.  
3.3.5 Thermogravimetry 
As no accurate information was available on silica concentrations of the elastomers 
from Providers 1 and 2, the concentrations had to be evaluated experimentally. In addi-
tion, analyzing all materials with the same method and device ensured data comparabil-
ity. The measurements were performed with a thermogravimeter (TGA/SDTA851e, 
Mettler Toledo, Greifensee, Switzerland) and a microbalance (XP6, Mettler Toledo, 
Greifensee, Switzerland). The thermogravimetric (TGA) analysis was performed for 
extruded, post-cured membrane tubes in open alumina crucibles in an inert (nitrogen) 
atmosphere, with a constant heating rate of 20 °C/min from 25 to 950 °C and an iso-
thermal hold at 950 °C for 15 minutes.  
 
Three parallel specimens were analyzed for each material. The ratios between residue 
weights and original specimen weights were calculated in percentages. Because the 
analysis was performed for extruded, post-cured tubes, the obtained weight percentages 
were expected to be higher than the added values of filler to the uncured elastomer. This 
is because mass loss occurs both during the compounding process (the addition of sili-
ca) and during the high temperature curing process as volatile byproducts and oligomers 
escape the material.  
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3.3.6 Release Rate in vitro 
In vitro drug release rates from the two products were determined with a release analy-
sis mimicking physiological conditions. The analyses were conducted according to in-
ternal guides of Bayer. Specimens were mounted in special holders inside glass bottles 
containing an aqueous dissolution medium. The bottles were closed and placed in a 
temperature-controlled shaking water bath. The temperature of the bath was maintained 
at 37 ± 0.5 °C and the shaking frequency and amplitude were kept constant. At prede-
termined intervals, the solutions were analyzed with HPLC, using a reversed-phase col-
umn and external calibration and a fresh dissolution medium was changed to the bottles. 
The release rate values were calculated by dividing the amount of API in the dissolution 
medium with the time that had passed since the previous sampling point.   
 
To draw meaningful conclusions from the data, specimen dimensions had to be meas-
ured. In the case of Product A, cross-sectional diameters and membrane thicknesses 
were measured from the ends of the reservoir-membrane cylinders before the cylinders 
were mounted on polyethylene bodies. For Product B, the dimension measurements 
were conducted, for practical reasons, after the release rate analysis, when the speci-
mens had dried. Both measurements were conducted with the same optical microscope 
(Quadra-Chek 300, Metronics, Bedford, New Hampshire, USA). The results are dis-
cussed in Sections 4.6 and 4.7.  
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4 RESULTS AND DISCUSSION 
In this chapter, the results of the study are first presented and discussed in individual 
sections for each analysis and then statistically analyzed in section 4.7. Regression 
models are created and possible sources of error are discussed at the end of this chapter.  
4.1 Rheometry 
Results from the rheological analyses are presented in Tables 6 and 7. As foreseen, all 
materials were very similar in terms of viscosity and curing characteristics. The small 
variations in silica concentration do seem to have an effect on the viscosity but it is very 
small. The mixing of peroxide (see subsection 3.2.2.3) to the new materials seems to 
have been successful.  
Table 6: Results of the individual complex viscosity (𝜼∗) measurements at different an-
gular frequencies (𝝎) for all membrane material batches used in this study.   
   𝜼∗ (𝒌𝑷𝒂 ∙ 𝒔) 
Provider Batch 
Reported silica 
content (w-%) 
𝛚 = 𝟎. 𝟏 𝐇𝐳 𝛚 = 𝟐. 𝟎 𝐇𝐳 𝛚 = 𝟐𝟎 𝐇𝐳 
1 For Product A ca. 35 104.4 12.1 1.88 
1 For Product B ca. 35 108.6 12.7 1.95 
2 For Product A 37  121.2 12.5 1.89 
2 For Product B 38 123.8 12.6 1.92 
3 Low silica 34.5 107.3 11.8 1.84 
3 Medium silica 35.1 117.2 12.6 1.92 
3 High silica 35.7 117.2 12.5 1.89 
 
Table 7: Results of the individual curing measurements for different membrane materi-
als. 90% cure corresponds to the point, where the storage modulus 𝑺’ equals 90 % of its 
predicted maximum (as calculated by the device).  
Provider Batch Reported silica 
content (w-%) 
Time at 90 
% cure (s) 
S’ at 90 % 
cure (dNm) 
Maximum 
S’ (dNm) 
1 For Product A ca. 35 98 11.3 12.4 
1 For Product B ca. 35 78 11.7 12.8 
2 For Product A 37 93 11.5 12.6 
2 For Product B 38 79 11.6 12.8 
3 Low silica 34.5 90 12.0 13.2 
3 Medium silica 35.1 76 11.8 13.0 
3 High silica 35.7 88 12.4 13.6 
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All measured viscosities at 2.0 Hz angular frequency were between 11.8 and 12.7 kPa·s 
and all materials achieved 90% cure in a maximum of 98 seconds and showed a maxi-
mum storage modulus between 12.4 and 13.6 dNm at the end of the 5 minute curing 
test. The curing test curves are shown in Appendix 1. Due to the lack of parallel exper-
imental points, no statistical conclusions can be drawn from the data. Nevertheless, suf-
ficient curing of extruded membrane tubes can be safely assumed, as much higher oven 
temperatures and longer post-curing times were used in the specimen preparation pro-
cess than in this curing analysis.  
4.2 API Content and Homogeneity 
Results of the API content analyses by HPLC are shown in Table 8. It can be seen that 
the mixture was homogeneous for both products. Some variations do exist between 
specimens, but since the concentrations are far above the solubility of the drug, no dif-
ferences in the short-term release rate should occur.   
 
Table 8: Statistics of the API Content and Homogeneity analysis 
 for the API-1 mixtures of both products. 
Statistics  
Reservoir API-1 content in 
Product A  [weight-%] (n=10) 
Reservoir API-1 content in  
Product B  [weight-%] (n=12) 
Mean 64.7 50.7 
Minimum value 64.2 50.4 
Maximum value 65.2 51.1 
Relative standard de-
viation (RSD) [%] 
0.4 0.4 
 
Drug concentration of the API-2 mixture in Product B was not analyzed chromatograph-
ically. According to earlier experience and visual examination of the mixture, it was 
concluded that the API-2 concentration was clearly above the solubility of the drug and 
that the mixture was homogeneous.  
4.3 Extractable Oligomers 
A summary of the results of the gravimetric analysis for membrane tubes used in Prod-
uct A and Product B is shown in Table 9. Tubes made from Provider 1 and 2 elastomers 
were analyzed only at the nominal thickness. Tubes made from Provider 3 materials 
were analyzed from all batches used in the final release rate specimens, with the excep-
tion of the point of high silica content and thin membrane for Product A, because no 
such membrane tube remained for the analysis.  
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Table 9: Amounts of hexane extracted oligomers in extruded membrane tubes. 
Provider 
Amount of extracted  
oligomers (weight-%) 
Product A Product B 
1 3.26 2.39 
2 3.40 3.63 
3 3.17–3.28 2.18–2.84 
 
No notable batch-to-batch differences can be found apart from the high value for Pro-
vider 2 Product B membrane. No obvious cause for this possible outlier could be found. 
It is possible that experimental error was involved. The test was not re-run due to lack 
of time and specimens.  
4.4 Mechanical Tests 
Results of the tensile tests are shown in Figures 21–26. Sample error bars shown in the 
graphs have a height of two standard deviations (±1 SD). The sample identification 
codes below the pillars are constructed in the following manner: the first digit refers to 
the material provider, the last digit refers to the thickness of the membrane (– refers to 
thin, + to thick and N to nominal) and the middle digit that is only seen with Provider 3 
batches refers to the silica concentration (L = low, M = medium, H = high).  
 
When conducting the tests for Product A membrane tubes, it was noticed that the exten-
someter caused the specimens to be strained unevenly. This was clearly visible during 
the test. Even though the supporting structures of the extensometer are designed so that 
a minimal amount of unwanted stresses are induced to a specimen, these small stresses 
were significant for the membrane tube specimens. The specimens were stretched to a 
larger extent above the extensometer than in other parts of the specimen. For the coated 
drug cores and Product B membrane tubes, the phenomenon was not clearly visible, as 
they were stiffer due to their larger cross-sectional areas. Based on these observations, 
the Product A membrane tube results are likely to be erroneous and, as a consequence, 
are not included.  
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Figure 21: Average values of tensile strain at break for Product A coated drug cores. 
See text for key. 
 
Figure 22: Average values of tensile strength for Product A coated drug cores. See text 
for key. 
 
Figure 23: Average values of tensile stress at 200% tensile strain for Product A coated 
drug cores. See text for key. 
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Figure 24: Average values of tensile strain at break for Product B membrane tubes. See 
text for key. 
 
Figure 25: Average values of tensile strength for Product B membrane tubes. See text 
for key. 
 
Figure 26: Average values of tensile stress at 200% tensile strain for Product B mem-
brane tubes. See text for key. 
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differences in extrusion parameters, such as die configuration and screw speed. Higher 
shear rates at the die will promote the orientation of polymer chains in the axial direc-
tion and consequently increase the tensile strength and stiffness of the extrudate. How-
ever, a clear correlation between process parameter values and the results was not 
found. The material silica concentration seems to have a small effect on the strength and 
the stiffness of the material, as would be expected. The increase in stiffness can be seen 
more clearly than the increase in strength. In general, variation between material batches 
is rather small and acceptable mechanical properties were observed for all materials.   
4.5 Thermogravimetry 
Results of the thermogravimetric (TGA) analysis for the extruded, post-cured mem-
brane tubes are shown in Table 10. The individual TGA curves can be found in Appen-
dix 2. It can be seen that for all batches, except the Provider 2 batch, the residues are 
markedly larger than the reported amounts of added silica. This is because volatile com-
pounds (oligomers and water) escape the material during the compounding process and 
some residual oligomers can also escape later during the curing and post-curing pro-
cesses. For Provider 2 materials, it seems that the reported concentration is not based on 
the added percentage but has been determined after the compounding via some charac-
terization method, most likely TGA.  
 
Table 10: Results of the thermogravimetric analysis for post-cured membrane tubes. 
   Thermogravimetric residue (w-%) 
Provider Reported 
silica content 
(w-%) 
Membrane 
thickness 
Specimen 
1 
Specimen 
2 
Specimen 
3 
Mean 
1 ca. 35 Nominal 38.6 38.7 38.7 38.6 
2 38 Nominal 38.1 38.0 38.1 38.1 
3 34.5 Thick 37.6 37.6 37.6 37.6 
3 35.1 Nominal 39.3 39.3 39.2 39.3 
3  35.7 Thick 39.6 39.6 39.6 39.6 
 
The residues were black in color. Since pure silica is white in color, this implies that the 
residues contain also some polymer degradation product besides the inert silica. It is 
known that the degradation process of linear PDMS in an inert atmosphere occurs 
through 𝑆𝑖 − 𝑂 bond scission and the subsequent formation of volatile cyclic oligomers. 
However, the polymer structure is not perfectly linear and of infinite molecular weight, 
and the end groups and crosslink-containing parts of the polymer may produce different 
degradation products than the linear parts. It is possible that reactions of these groups 
contribute to the black color and also, to small extent, to the residue weights.  
 
Another, more significant observation can be drawn from the values for the Provider 3 
sample: the relative magnitudes of the residues show that the reported silica concentra-
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tions may be erroneous. These findings were supported by a series of tests conducted 
previously for uncured, compounded elastomers, showing a very similar trend to the one 
obtained in the present study. The percentages obtained for post-cured membrane tubes 
were slightly larger than the ones obtained for the uncured elastomers in the previous 
study, since small amounts of volatile oligomers and crosslinking byproducts will es-
cape during the curing and post-curing processes.  
4.6 Release Rate in vitro 
The results of the release rate analyses will be analyzed statistically in section 4.7 in 
conjunction with results from TGA analyses and specimen dimension measurements, 
but some qualitative trends are discussed in this section. The average release rates from 
each specimen batch are presented as a function of time in Figures 27–29. See section 
3.2 to see the true specimen amounts. The sample identification codes below the pillars 
are constructed in the following manner: the first digit refers to the material provider, 
the last digit refers to the thickness of the membrane (– refers to thin, + to thick and N 
to nominal) and the middle digit that is only seen with provider 3 batches refers to the 
silica concentration (L = low, M = medium, H = high). 
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(a) 
 
(b) 
 
(c) 
Figure 27: Averaged API-1 release rates from Product A specimens with Provider 1 (a), 
Provider 2 (b) and Provider 3 (c) membrane materials. See text for key. 
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(a) 
 
(b) 
 
(c) 
Figure 28: Averaged API-1 release rates from Product B specimens with Provider 1 (a), 
Provider 2 (b) and Provider 3 (c) membrane materials. See text for key. 
 
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
R
e
le
as
e
 r
at
e
 (
m
as
s/
ti
m
e
) 
Time 
Product B, Provider 1, API-1 release rate 
1-
1N
1+
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
R
e
le
as
e
 r
at
e
 (
m
as
s/
ti
m
e
) 
Time 
Product B, Provider 2, API-1 release rate 
2-
2N
2+
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
R
e
le
as
e
 r
at
e
 (
m
as
s/
ti
m
e
) 
Time 
Product B, Provider 3, API-1 release rate 
3L-
3L+
3H-
3H+
3MN
 68 
 
(a) 
 
(b) 
 
(c) 
Figure 29: Averaged API-2 release rate from Product B with Provider 1 (a), Provider 2 
(b) and Provider 3 (c) membrane materials. See text for key.   
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The observed API-1 release rates corresponded perfectly with the theoretical considera-
tions of subsection 2.1.4.1 and specimen-to-specimen variations were small. Product A, 
having open ends, showed a significant burst of release in the first time points and a 
rapid decline of the release rate was observed with time (see Figure 27). The slope be-
came closer to zero as time progressed, and the later time points suggested that a nearly 
constant rate of release would be achieved in time. All Product B specimens showed a 
steady API-1 release rate after the small burst at the first time point – textbook behavior 
for a reservoir-type device (see Figure 28). However, for API-2 release from Product B, 
this was not the case (Figure 29).  
 
When the product is assembled, the drug core comes in contact with the membrane. As 
discussed in subsection 2.1.4.1, when this happens, the drug starts to dissolve into the 
membrane material and to diffuse through it. After a certain finite time of storage, a 
stable, location-independent concentration of drug is attained in the membrane. It can be 
rationalized that if this process has been completed before the product is introduced in 
vitro or in vivo, the product will show a burst release. If the process is far from com-
plete, the product will show a time lag in the release.  
 
This storage time, the time between the moment the API-2 core came in contact with the 
membrane and the introduction in vivo, was 6–7 days for all specimens. Thus, the dif-
ferences seen in Figure 29 cannot be fully explained by differences in storage time, 
which means that drug solubilities and/or diffusivities in the materials must be substan-
tially different. This suggests that Provider 1 and 2 materials differ by their composi-
tion. Provider 1 materials showed lower API-2 release rate values also at later time 
points, but the differences are more dramatic at early time points.  
 
Similar variation can also be seen between Provider 3 batches, but to a smaller extent 
(Figure 29c). Here, however, the variations can be explained simply by differences in 
membrane thickness as it obviously takes a longer time for the drug to diffuse evenly 
into a thicker membrane. Slight variations in the storage times can also explain a part of 
this small variation.   
 
It is interesting that these differences were noticeable only with API-2. This suggests 
that the chemical interactions of the material constituents with the two drug molecules 
are different. The chemical structures of the two active ingredients are, in fact, very dif-
ferent. The API-2 molecules are more polar than API-1 molecules, so they will have 
stronger interactions with highly polar silica particles. The observed differences could 
arise from different silica surface areas or surface treatments in the materials. A larger 
available silica surface area will result in increased binding sites for drug molecules and 
silica surface treatments can hinder (or promote) drug-silica interactions. These results 
show that if Provider 1 or Provider 3 materials are to be used in Product B, the storage 
time is a variable that must be controlled.  
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As mentioned in section 3.2.3.4, some voids, pockets of air, were found in the Product 
B API-2 sections before the release rate analysis. The pockets were also studied with a 
stereomicroscope (SZX12 + DP50, Olympus Optical Co. Ltd., Japan) after the analysis, 
when the specimen dimensions were measured. The voids were relatively small com-
pared to the size of the drug section and they were not in direct contact with the mem-
brane in any of the specimens. It could be seen that the amount of undissolved drug in 
the core mixture was smaller in the presence of a void that was close to the membrane. 
Nevertheless, the color suggested that there still was some crystalline drug left even in 
the thin sections of drug-elastomer mixture. Furthermore, the specimens with these 
voids did not show consistently smaller values of release rate. As a result, it was con-
cluded that the voids did not noticeably affect the short-term release rate.  
4.7 Statistical Analysis of Results 
4.7.1 Statistical Correlations 
The statistical correlations between the two predictor variables, the response variable, 
and other specimen variables were calculated. Dimension factor (𝐷𝐹) is a measure of 
specimen dimensions in the radial direction. It comes from equation (2.10) and is de-
fined as  
 
𝐷𝐹 =
1
ln(𝑏/𝑎)
 .        (4.1) 
 
The influence of membrane concentricity on drug release rate had been examined in 
earlier studies within the company. Therefore, it was also included in the analysis of this 
study, as cross-sectional variations in membrane thickness were observed. Membrane 
eccentricity is a measure of the degree of variation of membrane thickness in a speci-
men cross-section.  
 
 
Figure 30: Measurement of maximum and minimum membrane thicknesses from the 
cross-section to determine membrane eccentricity. 
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In this study, membrane eccentricity is defined as  
 
𝑀𝑒𝑚𝑏𝑟𝑎𝑛𝑒 𝑒𝑐𝑐𝑒𝑛𝑡𝑟𝑖𝑐𝑖𝑡𝑦 =  
𝑀𝑇𝑚𝑎𝑥−𝑀𝑇𝑚𝑖𝑛
1
2
(𝑏−𝑎)
 ,    (4.2)  
 
where 𝑀𝑇𝑚𝑎𝑥 is the highest and 𝑀𝑇𝑚𝑖𝑛 the lowest membrane thickness measured in a 
cross-section (see Figure 30). The correlation tables calculated with Minitab 17 are pre-
sented in Appendix 3. 
4.7.1.1 Product A 
Some conclusions drawn from the correlation tables in Appendix 3 are presented here 
for Product A. Firstly, the correlations of release rates with TGA residue values are 
stronger and more statistically significant than the ones with reported silica concentra-
tions. This supports the use of TGA residue values instead of reported concentrations in 
the statistical models. Secondly, correlation of release rate with the dimension factor 
becomes stronger and more statistically significant toward later time points, which cor-
responds to a decreased contribution of the open ends to the overall release rate.  Third-
ly, the correlations of release rate with TGA residue values decrease in strength and 
significance toward later time points. The correlations are not statistically significant 
apart from the first and perhaps the second time point (𝑝 =  0.000 and 𝑝 = 0.088, re-
spectively).  The cause for this trend remains unsettled. One would expect that release 
rate would correlate better with TGA residue values at later time points as the release 
becomes more membrane-controlled.  
 
Membrane eccentricity did not correlate significantly with drug release rates at any time 
point. Intuitively, no link should be present as the differences in membrane thickness 
average out each other in terms of diffusional path length. Length of the drug reservoir 
on assembled implants showed a statistically significant positive correlation with release 
rates at the last two time points (𝑝 = 0.075 and 𝑝 = 0.096). For earlier time points, no 
significant correlation was found, which was expected, since the burst effect dominates 
the release at early time points. The length obviously has a significant effect on the re-
lease rate, but the calculated correlations remained relatively insignificant simply due to 
very small length variations, the effects of which were lost in random error from the 
analytical methods.  
4.7.1.2 Product B 
Slightly different conclusions can be made from the correlation tables for Product B 
than were made for Product A. Firstly, release rates at all time points and for both APIs 
correlated strongly and very significantly with the dimension factor, as would be ex-
pected for a reservoir type device (𝑝 = 0.000). Again, the TGA residue values correlat-
ed slightly better with release rates than the reported silica concentrations did. However, 
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the correlations for neither of them were statistically significant, as p-values varied be-
tween 0.35 and 0.89.  
 
It is clear that a causal link exists between silica concentration and release rate. Howev-
er, because the studied range of concentrations is very narrow, the correlation is not 
seen as statistically significant in the analysis. Nevertheless, the variable will be used in 
the regression models as it gives consistently a small but negative correlation with the 
release rate and may improve the predictive capability of the model.  
 
Surprisingly, membrane eccentricity shows a significant correlation with release rates, 
but an even stronger correlation with the dimension factor. This is because systematical-
ly more eccentric membranes were obtained when manufacturing specimens with thick 
membranes, which means that the eccentricity is not by itself affecting the release rates.  
Instead, both the eccentricity and release rate are connected to the dimension factor.  
4.7.2 Regression Models 
As discussed in section 2.2.4.2, evidence suggests that the relationship between silica 
concentration and drug permeation rate through a PDMS membrane is at least close to 
linear for a rather wide range of concentrations. Very small concentration variations are 
studied in this work, so it is justifiable to study the dependence as linear.  In addition, 
the dimension factor is linearly proportional to the release rate (see Equations (2.10) and 
(4.1)). This justifies the use of multiple linear regression (MLR) without higher order 
terms to model the drug release.  
 
According to results from the TGA analysis and the statistical considerations presented 
above, the release rate variations between materials from different providers cannot be 
explained simply by differences in silica concentration. As a result, the predictive capa-
bility of a model that would be based on data from all materials would be poor. Conse-
quently, only Provider 3 materials were included in the statistical models.  
 
Since it was likely that the reported added silica concentrations of Provider 3 materials 
were erroneous and the release rate correlated better with the TGA residue values, the 
TGA residues were used as factors in the models instead of the reported silica concen-
trations. When using the models, it must be remembered that the cross-sectional dimen-
sions used in the models were measured before product assembly for Product A and 
after product assembly and release rate analysis for Product B. Product A dimensions 
could not be measured after the analysis, because the duration of the release rate analy-
sis was extended for some of the specimens (for purposes beyond this thesis). Conse-
quently, the specimens were not available for dimension measurements.  
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4.7.2.1 Product A 
For practical reasons, it was decided that Product A release rate should be modelled at 
the first, the middlemost and the last time points. Individual linear models for these time 
points were created, following the regression equation 
 
𝑅𝑅 = ?̂?0 + ?̂?1(𝐷𝐹) + ?̂?2(𝑇𝐺𝐴)  ,      (4.2) 
 
where 𝑅𝑅 is the drug release rate (in certain units of mass/time), 𝐷𝐹 is the unitless di-
mension factor and 𝑇𝐺𝐴 is the thermogravimetric residue (in w-%). The regression co-
efficients and model parameters calculated with Minitab 17 software are presented in 
Tables 11 and 12, respectively.  
Table 11: Estimated values, standard errors and p-values of the coefficients of the re-
gression models for Product A drug release rate at three different time points. 
Timepoint Coefficient Estimated 
Value 
Coefficient of standard 
error 
p-value 
First  ?̂?0 5.289 0.786 0.000 
?̂?1 0.0511 0.0284 0.088 
?̂?2 –0.0975 0.0201 0.000 
Middle  ?̂?0 1.451 0.293 0.000 
?̂?1 0.1798 0.0106 0.000 
?̂?2 – 0.02810 0.00747 0.001 
Last  ?̂?0 1.475 0.206 0.000 
?̂?1 0.18604 0.00746 0.000 
?̂?2 – 0.03346 0.00526 0.000 
 
Table 12: Parameters of the regression models for Product A. S is the standard distance 
of data points from the regression line and R2 is the coefficient of determination.  
Timepoint S R2 (%) Adjusted R2 (%) 
First 0.0851 59.05 54.74 
Middle 0.0317 94.16 93.55 
Last 0.0223 97.25 96.97 
 
It can be seen from the R2-values that only the middlemost and last time point models 
can adequately model the release rate. The last time point model can explain 97.25% of 
the total variance in the data, which is a very good value for a regression model. The p-
values of the model coefficients show that the chosen variables give significant contri-
butions to the model, the effect of dimension factor at the first time point being the least 
significant (𝑝 = 0.088). The dimension factor generally shows a stronger contribution 
than the silica concentration, as expected by the correlation coefficients presented pre-
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viously. The distributions of model residuals are shown in Figure 31 and the deviations 
of observed values from fitted values are shown in Figure 32 with a straight line repre-
senting a perfect fit.  
 
   
   
(a) (b) (c) 
Figure 31: Normal probability plots and histograms of the residuals of the regression 
models for Product A drug release rate at the first (a), middlemost (b) and last (c) time 
points. 
 
(a) 
 
(b) 
 
(c) 
Figure 32: Plots of observed vs. predicted values of Product A drug release rate at the 
first (a), middlemost (b) and last (c) time points. The graphs have different axis value 
ranges.  
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The model residual plots in Figure 31 show agreeable residual distributions for the first 
and last time point models and a highly normal distribution for the middlemost point 
model. A slight S-shape can be observed in all graphs. Moderate departures from nor-
mality do not seriously affect the results with large sample sizes. Figure 32 shows very 
clearly the differences in predictive capabilities between the models. The average dis-
tance of points from the regression line is markedly smaller with later time point mod-
els. Poor predictive capability of the first time point model was expected, because the 
model only includes variables related to the membrane and the release from the open 
ends is independent of the membrane.  
4.7.2.2 Product B 
The release rate of Product B was modelled somewhat differently than that of Product 
A. Since the API-1 release rate remained fairly constant after the initial burst at the first 
time point, it was decided that all time points apart from the first one should be included 
in a single model. The regression coefficients and model parameters are listed in Tables 
13 and 14. No successful model could be created for the API-2 release rate as a function 
of membrane thickness and TGA residue. Additional studies that take the storage time 
dependent behavior into account will be needed if a useful model is to be created for 
API-2 release rate. The distribution of residuals and an observed vs. predicted values 
plot are shown in Figure 33.   
 
Table 13: Estimated values, standard errors and p-values of the coefficients of the re-
gression model for Product B API-1 release rate. 
Model Coefficient Estimated 
Value 
Coefficient standard error p-value 
API-1 release,  
Time points 2–8 
 
?̂?0 0.861 0.120 0.000 
?̂?1 0.17738 0.00222 0.000 
?̂?2 –0.01956 0.00304 0.000 
 
 
Table 14: Parameters of the regression model for Product B. S is the standard distance 
of data points from the regression line and R2 is the coefficient of determination. 
Model S R2 (%) Adjusted R2 (%) 
API-1 release,  
time points 2–8 
0.03636 97.42 97.39 
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(a) (b) 
Figure 33: (a) Normal probability plots and histograms of the residuals of the regres-
sion model for Product B. (b) A plot of observed vs. predicted values for the model with 
a line representing perfect fit. 
 
The model shows high predictive capability as it explains 97.42% of total variance in 
the data (Table 14). According to Figure 33, the model residuals follow a highly normal 
distribution. Two possible outliers can be seen in the graphs, but these were not exclud-
ed since the values were not dramatically different and no obvious cause for the devia-
tion was found. The grouping of points seen in Figure 33b is a result of using the same 
dimension factor and TGA residue values for each time point. The individual data 
points in the vertical “pillars” represent the values obtained at different time points for a 
single specimen.  
4.7.3 Other Sources of Variance 
A considerable amount of response variance can result from differences in drug section 
lengths. Based on process control limits, the length variations may be up to ± 1.6% of 
nominal length for Product A and up to ± 4.0% of nominal length for Product B API-1 
section. This will, according to equation (2.10), result in similar variation in steady-state 
release rate. To improve the predictive capability of the model, it would have been pos-
sible to include the drug section length in the analysis as a covariate. However, Product 
B drug section lengths could not be measured accurately after the release rate analysis, 
because the specimens were mistakenly cut for the cross-sectional analysis before any 
length measurements were made.  
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On one hand, it would have been wise to prepare specimens that cover the whole range 
of drug section lengths allowed by the established process control limits, because then 
the models would better correspond to a real product manufacturing situation. In fact, 
this was the case for Product A.  Product B drug section lengths were not accurately 
measured for reasons discussed above, so their true variance remains unknown. On the 
other hand, previous studies suggest that the within-tolerance length variations do not 
cause statistically significant differences in the release rate.  
 
 78 
5 CONCLUSIONS 
In this thesis work, the effect of fumed silica concentration of a polydimethylsiloxane 
elastomer membrane on the drug release rates from cylindrical, diffusion-controlled 
drug delivery devices was studied. The goals of the thesis were to find suitable elasto-
mer compositions for two products so that certain predetermined release rates of two 
drugs, API-1 and API-2, would be achievable with materials from a new provider. In 
addition, the effects of silica concentration and cross-sectional dimensions of the prod-
uct on drug release rates were to be modelled statistically.  
 
Materials from three providers were studied. Materials from different providers showed 
somewhat different behavior in terms of mechanical, thermogravimetric and diffusional 
properties. Since it is known that the base polymers have similar chemical structures, 
the differences in properties are likely due to differences in molecular weight distribu-
tion, amount and type of peroxide initiator used, silica surface area or compounding 
parameters.  
 
Even with perfectly identical material constituents, different compounding parameters 
could cause differences in material behavior, because the silica particles are coated with 
a PA-fluid during the compounding process. Poorly coated particles have more free 
hydroxyl groups available for drug-silica interactions and can form agglomerates more 
easily. Gel permeation chromatrography and peroxide quantification could have been 
used to rule out the effects of molecular weight and initiator concentration. The precise 
reason for these differences remains unsettled. The cause was not pursued further, since 
it was beyond the scope of this thesis.  
 
Suitable composition ranges for the new materials were successfully determined for 
both products and regression models were created for API-1 release rates from the 
products. Additional studies should be conducted to quantify the effect of silica on 
steady-state API-2 release rate, since in these tests, the data was rendered partly invalid 
by differences in initial API concentrations in the membrane. This, however, raised an 
important point: the storage time between manufacturing and use or analysis of products 
with API-2 reservoirs must be controlled if the new materials are to be used for the 
product. It is likely that this will not be an issue for sterilized products, because sterili-
zation carried out at elevated temperatures may provide sufficient heat and time to ac-
celerate the diffusion and allow the membrane to be saturated with drug.   
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When comparing the results to internal product specifications, it was concluded that the 
use of a single elastomer composition for both products is possible, but it limits the pos-
sible ranges of product dimensions and may affect the specimen manufacturing process-
es. If the new materials are to be used, verification studies should be conducted near the 
optimal process parameters to validate the conclusions of this study and to set new pro-
cess control limits. The effects of membrane thickness variations on the fluency and 
throughput of the assembly processes should also be evaluated.  
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APPENDICES 
 
 
Appendix 1: Curing curves 
 
 
 
Appendix Figure 1: Graphical presentation of results from the curing analysis for all 
used coating membrane material batches. 𝑺’ is the material storage modulus. See sec-
tions 3.3.1 and 4.1 for details.  
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Appendix 2: Thermogravimetric curves 
 
 
(1) 
 
(2) 
 
(3) 
Appendix Figure 2: TGA curves for the analyzed membrane tubes: Provider 2 material, 
three parallel measurements (1-3). 
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(1) 
 
(2) 
 
(3) 
Appendix Figure 3: TGA curves for the analyzed membrane tubes: Provider 1 material, 
three parallel measurements (1-3). 
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(1) 
 
(2) 
 
(3) 
Appendix Figure 4: TGA curves for the analyzed membrane tubes: Provider 3 material 
with lowest silica concentration, three parallel measurements (1-3). 
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(1) 
 
(2) 
 
(3) 
Appendix Figure 5: TGA curves for the analyzed membrane tubes: Provider 3 material 
with medium silica concentration, three parallel measurements (1-3). 
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(1) 
 
(2) 
 
(3) 
Appendix Figure 6: TGA curves for the analyzed membrane tubes: Provider 3 material 
with the highest silica concentration, three parallel measurements (1-3). 
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Appendix 3: Correlation coefficient tables 
 
Appendix Table 1: Calculated correlation coefficients and p-values for Product A re-
sults. 
  API-1 release rate at time point 
Dimension 
factor 
Membrane 
ecc. 
Length 
prior to 
assembly 
Length 
after 
assembly 
Reported 
silica 
conc. 
1 2 3 4 5 
API-1 
release 
rate at 
time point 
2 Correlation 0.342 
         
p-value 0.119 
         
3 Correlation 0.435 0.627 
        
p-value 0.043 0.002 
        
4 Correlation 0.441 0.628 0.984 
       
p-value 0.040 0.002 0.000 
       
5 Correlation 0.441 0.618 0.983 0.985 
      
p-value 0.040 0.002 0.000 0.000 
      
Dimension 
factor 
Correlation 0.285 0.515 0.948 0.956 0.956 
     
p-value 0.199 0.014 0.000 0.000 0.000 
     
Membrane ecc. 
Correlation –0.262 –0.151 –0.238 –0.235 –0.305 –0.229 
    
p-value 0.240 0.503 0.286 0.292 0.168 0.305 
    
Length prior to 
assembly 
Correlation –0.497 –0.141 –0.227 –0.255 –0.297 –0.157 0.607 
   
p-value 0.019 0.531 0.309 0.252 0.179 0.484 0.003 
   
Length after 
assembly 
Correlation –0.119 0.147 0.351 0.387 0.364 0.367 0.339 0.310 
  
p-value 0.599 0.515 0.109 0.075 0.096 0.093 0.123 0.161 
  
Reported silica 
conc. 
Correlation –0.662 –0.265 –0.165 –0.189 –0.200 0.009 0.634 0.688 0.362 
 
p-value 0.001 0.233 0.463 0.399 0.372 0.968 0.002 0.000 0.098 
 
TGA residue 
Correlation –0.722 –0.372 –0.236 –0.262 –0.270 –0.029 0.459 0.582 0.182 0.946 
p-value 0.000 0.088 0.290 0.238 0.225 0.896 0.031 0.004 0.418 0.000 
 
Appendix Table 2: Calculated correlation coefficients and p-values for Product B API-1 
results. 
  API-1 Release rate at time point Dimensi-
on factor 
Membra-
ne ecc. 
Reported 
silica 
conc. 
1 2 3 4 5 6 7 8 9 
API-1 
release 
rate at 
time point 
2 Correlation 0.989 
           
p-value 0.000 
           
3 Correlation 0.990 0.997 
          
p-value 0.000 0.000 
          
4 Correlation 0.980 0.982 0.988 
         
p-value 0.000 0.000 0.000 
         
5 Correlation 0.989 0.994 0.997 0.991 
        
p-value 0.000 0.000 0.000 0.000 
        
6 Correlation 0.991 0.995 0.998 0.988 0.998 
       
p-value 0.000 0.000 0.000 0.000 0.000 
       
7 Correlation 0.991 0.997 0.999 0.990 0.997 0.998 
      
p-value 0.000 0.000 0.000 0.000 0.000 0.000 
      
8 Correlation 0.988 0.995 0.998 0.989 0.996 0.998 0.999 
     
p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
     
9 Correlation 0.989 0.995 0.998 0.990 0.998 0.998 0.999 0.998 
    
p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
    
Dimension factor 
Correlation 0.973 0.989 0.991 0.978 0.984 0.986 0.990 0.990 0.990  
  
p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000  
  
Membrane ecc. 
Correlation 0.700 0.708 0.703 0.712 0.689 0.696 0.707 0.704 0.700 0.730  
 
p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000  
 
Reported silica 
conc. 
Correlation –0.142 –0.058 –0.086 –0.090 –0.099 –0.107 –0.089 –0.089 –0.069 0.006 –0.045  
p-value 0.529 0.797 0.705 0.691 0.661 0.635 0.695 0.694 0.761 0.979 0.842  
TGA residue 
Correlation –0.208 –0.128 –0.152 –0.168 –0.166 –0.172 –0.158 –0.161 –0.136 –0.077 –0.247 0.946 
p-value 0.353 0.571 0.500 0.454 0.460 0.443 0.483 0.474 0.548 0.732 0.268 0.000 
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Appendix Table 3: Calculated correlation coefficients and p-values for Product B API-2 
results.  
  API-2 Release rate at time point Dimensi-
on factor 
Membra-
ne ecc. 
Reported 
silica 
conc. 
1 2 3 4 5 6 7 8 9 
API-2 
release 
rate at 
time point 
2 Correlation 0.982 
           
p-value 0.000 
           
3 Correlation 0.981 0.996 
          
p-value 0.000 0.000 
          
4 Correlation 0.977 0.993 0.996 
         
p-value 0.000 0.000 0.000 
         
5 Correlation 0.976 0.984 0.994 0.994 
        
p-value 0.000 0.000 0.000 0.000 
        
6 Correlation 0.971 0.981 0.993 0.993 0.998 
       
p-value 0.000 0.000 0.000 0.000 0.000 
       
7 Correlation 0.961 0.972 0.987 0.987 0.994 0.997 
      
p-value 0.000 0.000 0.000 0.000 0.000 0.000 
      
8 Correlation 0.962 0.972 0.986 0.989 0.993 0.997 0.996 
     
p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
     
9 Correlation 0.953 0.961 0.976 0.981 0.986 0.990 0.994 0.996 
    
p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
    
Dimension factor 
Correlation 0.912 0.952 0.934 0.928 0.919 0.904 0.900 0.894 0.888 
   
p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
   
Membrane ecc. 
Correlation 0.565 0.646 0.601 0.600 0.570 0.552 0.552 0.539 0.530 0.731 
  
p-value 0.006 0.001 0.003 0.003 0.006 0.008 0.008 0.010 0.011 0.000 
  
Reported silica 
conc. 
Correlation –0.081 –0.039 –0.086 –0.030 –0.093 –0.099 –0.102 –0.060 –0.030 0.070 0.128 
 
p-value 0.719 0.861 0.704 0.894 0.680 0.662 0.653 0.791 0.893 0.756 0.571 
 
TGA residue 
Correlation –0.126 –0.123 –0.149 –0.095 –0.141 –0.145 –0.140 –0.101 –0.058 –0.047 –0.092 0.946 
p-value 0.578 0.585 0.508 0.675 0.533 0.519 0.533 0.654 0.797 0.834 0.683 0.000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
